[STUDY_ID_REMOVED]
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217100] OF IN- TEXT TA BLES .......................................................................................................7  
SYNOPSIS ...................................................................................................................... ................8  
ABBREVIATIONS ................................................................................................................. .....14  
1. BACKGROUND .........................................................................................................16  
1.1. Disease/Histology .........................................................................................................16  
1.1.1.  Disease B ackground ......................................................................................................16  
1.1.2.  Current Treatment Options ...........................................................................................17  
1.2. Ibrutinib Overview ........................................................................................................18  
1.2.1.  Summary of Nonclinical Data .......................................................................................18  
[IP_ADDRESS].  Pharmacology ................................................................................................................18  
[IP_ADDRESS].  Safety Pharmacology and Toxicology ..........................................................................19  
1.2.2.  Summary of Clinical Data .............................................................................................19  
[IP_ADDRESS].  Pharmacokinetics and Product Metabolism ..................................................................19  
1.2.3.  Summary of Clinical Safety ..........................................................................................20  
[IP_ADDRESS].  Monotherapy Studies ....................................................................................................20  
[IP_ADDRESS].  Combination Studies .....................................................................................................21  
[IP_ADDRESS].  Chronic GVHD Study ...................................................................................................21  
1.2.4.  Risks ......................................................................................................................... .....22  
[IP_ADDRESS].  Atrial Fibrillation ..........................................................................................................22  
[IP_ADDRESS].  Bleeding-related Events ................................................................................................22  
[IP_ADDRESS].  Cytopenias .................................................................................................................... .22 
[IP_ADDRESS].  Diarrhea ...................................................................................................................... ...22  
[IP_ADDRESS].  Infections .................................................................................................................... ...22  
[IP_ADDRESS].  Interstitial Lung Disease (ILD) .....................................................................................23  
[IP_ADDRESS].  Non-melanoma Skin Cancer .........................................................................................23  
[IP_ADDRESS].  Rash ...............................................................................................................................23  
[IP_ADDRESS].  Hypertension .................................................................................................................[ADDRESS_217101] Disease ................................28  
1.4. Study Rationale .............................................................................................................28  
2. STUDY OBJECTIVES ...............................................................................................29  
2.1. Primary Objective .........................................................................................................29  
2.2. Secondary Objective(s) .................................................................................................29  
2.3. Exploratory Objective(s) ...............................................................................................29  
3. STUDY DESIGN .........................................................................................................30  
3.1. Overview of Study Design ............................................................................................30  
3.1.1.  Study Schema ................................................................................................................31  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217102] SELECTION ............................................................................................32  
4.1. Inclusion Criteria ...........................................................................................................32  
4.2. Exclusion Criteria..........................................................................................................33  
5. TREATMENT OF SUBJECTS .................................................................................35  
5.1. Treatment Allocation and Blinding ...............................................................................35  
5.1.1.  Randomized Double-blind Phase ..................................................................................35  
[IP_ADDRESS].  Blinding ...................................................................................................................... ...35  
5.2. Study Treatment ............................................................................................................36  
5.3. Study Medication ..........................................................................................................36  
5.3.1.  Ibrutinib/Placebo ...........................................................................................................36  
[IP_ADDRESS].  Formulation/Packaging/Storage ....................................................................................36  
[IP_ADDRESS].  Dose and Administration...............................................................................................37  
[IP_ADDRESS].  Overdose ...................................................................................................................... .37 
[IP_ADDRESS].  Dose Modification for Adverse Reactions ....................................................................37  
[IP_ADDRESS].  Dose Modification for Subjects with Hepatic Impairment ...........................................39  
[IP_ADDRESS].  Ibrutinib/Placebo Hold after Withdr awal of All Immunosuppressants.........................39  
5.3.2.  Prednisone .................................................................................................................... .40 
[IP_ADDRESS].  Formulation/Packaging/Storage ....................................................................................40  
[IP_ADDRESS].  Dose and Administration...............................................................................................40  
[IP_ADDRESS].  Overdose ...................................................................................................................... .41 
[IP_ADDRESS].  Dose Modification for Adverse Reactions ....................................................................42  
5.4. Criteria for Permanent Disconti nuation of Ibrutinib/Placebo .......................................42  
6. CONCOMITANT MEDICAT IONS/PROCEDURES .............................................42  
6.1. Permitted Concomitant Medications .............................................................................42  
6.1.1.  Ancillary Therapy a nd Supportive Care .......................................................................42  
6.1.2.  Systemic Immunosuppressant Therapy.........................................................................43  
6.2. Medications to be Used with Caution ...........................................................................43  
6.2.1.  CYP3A Enzyme Inhibitors/Inducers.............................................................................[ADDRESS_217103] Their Plasma C oncentrations Altered by [CONTACT_183939] ..................44  
6.2.3.  Antiplatelet Agents and Anticoagulants........................................................................44  
6.3. Other Systemic Immunosuppressant Therapy for cGVHD ..........................................45  
6.4. Guidelines for Ibrutinib Management with Surgeries or Procedures............................45  
6.4.1.  Minor Surgical Procedures ............................................................................................45  
6.4.2.  Major Surgical Procedures ............................................................................................45  
7. STUDY EVALUATIONS ...........................................................................................46  
7.1. Description of Procedures .............................................................................................46  
7.1.1.  Assessments ..................................................................................................................4 6 
[IP_ADDRESS].  Informed Consent Form (ICF) ......................................................................................46  
[IP_ADDRESS].  Confirm E ligibilit y ........................................................................................................46  
[IP_ADDRESS].  Medical History and Demographics .............................................................................46  
[IP_ADDRESS].  Prior and Concomita nt Medications..............................................................................46  
[IP_ADDRESS].  Adverse Events..............................................................................................................47  
[IP_ADDRESS].  Physical Examination ....................................................................................................47  
[IP_ADDRESS].  Karnofsky/Lansky Performance Scale ..........................................................................47  
[IP_ADDRESS].  Vital Signs ................................................................................................................... ..47 
7.1.2.  Laboratory .................................................................................................................... .47 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 5 [IP_ADDRESS].  Hematology ...................................................................................................................4 7 
[IP_ADDRESS].  Chemistry (Serum) ........................................................................................................47  
[IP_ADDRESS].  Infection Surveillance ...................................................................................................48  
[IP_ADDRESS].  Coagulation Studies ......................................................................................................48  
[IP_ADDRESS].  Hepatitis Serologies ......................................................................................................48  
[IP_ADDRESS].  Serum Immunoglobulins ...............................................................................................48  
[IP_ADDRESS].  Pregnancy Test ..............................................................................................................48  
7.1.3.  Diagnostics/Procedures .................................................................................................48  
[IP_ADDRESS].  Electrocardiograms (ECG) ............................................................................................48  
[IP_ADDRESS].  Forced Expi[INVESTIGATOR_1814] 1 Second (FEV1)...........................................................49  
7.1.4.  Pharmacokinetics/Biomarkers.......................................................................................49  
[IP_ADDRESS].  Pharmacokinetics ..........................................................................................................49  
[IP_ADDRESS].  Biomarkers and Pharmacodynamic Studies ..................................................................49  
[IP_ADDRESS].  Biomarker DNA and RNA Sequencing ........................................................................50  
7.2. Sample Collection and Handling ..................................................................................50  
7.3. Efficacy Evaluations .....................................................................................................50  
7.3.1.  NIH Consensus Panel Response Criteria ......................................................................50  
7.3.2.  Lee cGVHD Symptom Scale and SF-36 Questionnaire ...............................................51  
7.3.3.  Late effects surveillance for adoles cents (<22 years at randomization) .......................51  
8. STUDY PROCEDURES .............................................................................................51  
8.1. Screening Phase ............................................................................................................51  
8.1.1.  Screening/Consenting Visit ...........................................................................................51  
8.2. Treatment Phase ............................................................................................................52  
8.2.1.  Treatment Visits ............................................................................................................52  
[IP_ADDRESS].  Week 1 Day 1 ................................................................................................................52  
[IP_ADDRESS].  Week 2 ........................................................................................................................ ..53 
[IP_ADDRESS].  Week 5, 9, 13, 17, 21, 25 ..............................................................................................54  
[IP_ADDRESS].  Week 37, 49, and every 12 week s thereafter (Â± 7 days) ...............................................[ADDRESS_217104] COMPLETION AND WITHDRAWAL ................................................58  
9.1. Completion .................................................................................................................... 58 
9.2. Discontinuation from Ibrutinib/Placebo ........................................................................58  
9.3. Withdrawal from Study .................................................................................................58  
10. STATISTICAL METHODS AND ANALYSIS .......................................................59  
10.1.  Analysis Sets .................................................................................................................59  
10.1.1.  Intention-to-Treat Population (ITT) ..............................................................................59  
10.1.2.  Safety Population (SP) ..................................................................................................[ADDRESS_217105] Information .......................................................................................................60  
10.4.  Efficacy Analys es..........................................................................................................60  
10.4.1.  Primary Efficacy Endpoint ............................................................................................60  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 6 10.4.2.  Secondary Endpoints for Efficacy ................................................................................60  
10.4.3.  Exploratory Endpoints ..................................................................................................61  
10.5.  Safety Analysis .............................................................................................................62  
10.6.  Interim Futility Review .................................................................................................63  
10.7.  Data Monitoring Committee (DMC) ............................................................................63  
11. ADVERSE EVENT REPORTING ............................................................................64  
11.1.  Definitions .....................................................................................................................64  
11.1.1.  Adverse Events..............................................................................................................64  
11.1.2.  Serious Adverse Events.................................................................................................65  
11.1.3.  Severity Criteria (Grade 1-5) ........................................................................................66  
11.1.4.  Causality (Attribution) ..................................................................................................[ADDRESS_217106] (AESI) ...................................................................70  
[IP_ADDRESS].  Major Hemo rrhage ........................................................................................................[ADDRESS_217107] (IRB), Research Ethics Board (REB) and Independent Ethics Committee (IEC) Approval ................................................................................[ADDRESS_217108] Maintenance ...............................................................73  
12.8.  Investigational Study Drug Accountability ...................................................................73  
12.9.  Study Monitoring/Audit Requirements .........................................................................74  
12.10.  Investigator Responsibilities .........................................................................................75  
12.11.  Sponsor Responsibilities ...............................................................................................75  
12.12.  Financial Disclosure ......................................................................................................75  
12.13.  Liability and Clinical Trial Insurance ...........................................................................76  
12.14.  Protocol Amendments ...................................................................................................76  
12.15.  Publication of Study Results .........................................................................................76  
12.16.  Study Discontinuation ...................................................................................................77  
13. REFERENCES ............................................................................................................78  
14. APPENDICES .............................................................................................................82  
 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217109] OF APPENDICES 
Appendix A.  Schedule of Assessments .......................................................................................83  
Appendix B.  Schedule of Assessments for Phar macokinetics, Pharmacodynamics, 
Biomarker and T/B/NK..........................................................................................87  
Appendix C.  Karnofsky/Lansky Performance Status ..................................................................88  
Appendix D.  Inhibitors and Inducers of CYP3A ........................................................................89  
Appendix E.  Child-Pugh Score for Subjects with Chronic Liver Impairment ...........................90  
Appendix F.  Lee cGVHD Symptom Scale .................................................................................91  
Appendix G.  SF-36 Questionnaire ..............................................................................................93  
Appendix H.  Chronic GVHD Activity Assessment â€“ Clinician .................................................99  
Appendix I.  Response Determination for Chronic GVHD Clinical Trials based on 
Clinician Assessments .........................................................................................102  
Appendix J.  Chronic GVHD Activity Assessment  Patient Se lf Report ...............................104  
Appendix K.  Prednisone Equi valents Table ..............................................................................105  
Appendix L.  Summary of Ancillary Therapy a nd Supportive Care Interventions ...................106  
Appendix M.  Diagnosis of cGVHD  Signs and Symptoms of cGVHD ..................................110  
Appendix N.  Staging of cGVHD ...............................................................................................114  
Appendix O.  NIH Global Severity/Staging of cGVHD ............................................................[ADDRESS_217110] OF IN-TEXT TABLES  
Table 1.  Ibrutinib/Placebo Dose Modifications ...................................................................38  
Table 2.  Ibrutinib/Placebo Dose Reduction Levels .............................................................38  
Table 3.  Ibrutinib/Placebo Dose Modifications for Subjects with Hepatic Impairment ......39  
Table 4.  Prednisone Tape r Schedule ....................................................................................41  
Table 5.  Ibrutinib/Placebo Dose Modifications for Concomitant Use of CYP3A Inhibitors ................................................................................................................44
 
  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 8 SYNOPSIS 
Study Title: A Randomized, Double-Blind Phase [ADDRESS_217111] Disease (cGVHD) 
Protocol Number: PCYC-1140-IM 
Study Phase: 3 
Study Duration: Estimated to be up to [ADDRESS_217112] and Reference Therapy: Ibrutinib (IMBRUVICA
Â®) will be supplied as [ADDRESS_217113] gelatin capsules for oral (PO) administration.  
Placebo will be supplied as hard gelatin capsules and will look 
identical to ibrutinib capsules.  
Objectives: Primary Objective: 
To evaluate the efficacy of ibrutinib in combination with prednisone 
(Arm A) versus placebo in combination with prednisone (Arm B) 
based on the response rate at 48 weeks (the proportion of responders [CR or PR]) as determined by [CONTACT_183940]. 
Secondary Objectives: 
To compare the two treatment arms in terms of the following: 
Efficacy 
x Response rate at 24 weeks (the proportion of responders [CR or 
PR]) as defined by [CONTACT_183941] (2014) 
x Duration of response (DOR) 
x Proportion of subjects obtaining steroid dose level less than 0.15 mg/kg/d at 24 weeks 
x Time to withdrawal of all immunosuppressants (with the 
exception of ibrutinib/placebo)  
x Overall survival (OS) 
x Lee cGVHD symptom scale improvement 
Safety 
x Safety and tolerability  
x Differences in steroid-related morbidities (eg, hyperglycemia, 
hypertension)  
Study Design: This is a Phase 3, multicenter, international, randomized, double-blind 
study of oral ibrutinib in combination with prednisone versus placebo 
in combination with prednisone in subjects with new onset chronic 
GVHD. 
Approximately [ADDRESS_217114] Criteria, will be randomized in a 1:1 ratio to receive either ibrutinib in 
combination with prednisone (Arm A) or placebo in combination with 
prednisone (Arm B). 
Treatment with ibrutinib/placebo will be administered continuously 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 9 until unacceptable toxicity, progression of the underlying disease, 
death, or the start of a new systemic treatment for cGVHD. 
Ibrutinib/placebo can be discontinued after response in cGVHD disease 
symptoms and withdrawal of ot her systemic immunosuppressants 
(Section [IP_ADDRESS]). 
Corticosteroid therapy will be tapered as per a standard taper regimen 
with the goal of reducing exposure to high-moderate dose 
corticosteroids as quickly as possible according to clinical severity of cGVHD. A standard steroid taper schedule is provided in the protocol 
as guidance for clinicians ( Table 4 ). 
The primary endpoint is the response rate at [ADDRESS_217115] Criteria 
(2014) and must occur: 
x In the absence of new therapy for cGVHD 
x In the absence of progression of the underlying disease that was 
the indication for transplant, or post-transplant 
lymphoproliferative disease (PTLD), or death 
Secondary endpoints will assess for additional clinical benefit including Week-24 response, DOR, corticosteroid dose reduction, 
time to withdrawal of all immunosuppressants, OS, and Lee cGVHD 
symptom scale. 
The randomization between arms will be stratified according to: 
x Age group (12 to <22 \HDUVROGYVÂ• 22 years old) 
x NIH Global Severity grade (moderate vs. severe) 
x Ongoing use of systemic immunosuppressants that were initiated 
for either treatment of or prophylaxis for acute GVHD (Yes vs. 
No) 
Population: x Subjects with new onset moderate or severe cGVHD as defined 
by [CONTACT_183942] 
(Jagasia 2015 ) 
x Subjects must be in need of systemic treatment for cGVHD with 
corticosteroids 
Centers: Multi-center, International  
Inclusion Criteria:  Eligible subjects will meet all of the following criteria: 
1. New onset moderate or severe cGVHD as defined by [CONTACT_183943] (2014, see Appendix M, 
Appendix N , Appendix O ). 
2. History of an allogeneic hematopoietic cell transplant.  
3. Need for systemic treatment with corticosteroids for cGVHD. 
4. No previous systemic treatment for cGVHD (including 
extracorporeal photopheresis [ECP]). 
5. Participants may be receiving other immunosuppressants for the 
prophylaxis or treatment of acute GVHD but if the subject is 
receiving prednisone for prophylaxis or treatment of acute GVHD 
it must be at or below 0.5 mg/kg/d.  
6. Participants may have received pre-transplant BTK inhibitors for 
other reasons besides cGVHD such as for the treatment of 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217116] received a BTK 
inhibitor since the time of transplant. 
7. Age Â•12 years old.  
8. Karnofsky or Lansky (subjects <16 years) performance score Â•60. 
9. Adequate renal function defined as an estimated Creatinine 
&OHDUDQFHÂ•P/PLQ&RFNFURIW -Gault formula) 
10. Adequate hepatic function as defined by: 
x 7RWDOELOLUXELQRIÂ”[8/1 (unless of non-hepatic origin 
or due to Gilbertâ€™s Syndrome) or 
x Total bilirubin of > 1.[ADDRESS_217117] if due to GVHD 
11. Adequate hematological function defined as: 
x $EVROXWHQHXWURSKLOFRXQWÂ•[9/L and off growth factor 
support for 7 days 
x 3ODWHOHWVÂ•[9/L and no transfusion for 7 days 
12. PT/INR <1.[ADDRESS_217118] and PTT (aPTT) <1.[ADDRESS_217119] (unless 
abnormalities are unrelated to coagulopathy or bleeding disorder). 
When treated with warfarin or other vitamin K antagonist, then 
,15Â” ( Section 6.2.3). 
Ethical/Other 
13. Male and female subjects of reproductive potential who agree to 
use both a highly effective methods of birth control (eg, implants, 
injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence
1, or sterilized partner) and a 
barrier method (eg, condoms, cervical ring, sponge, etc.) during the period of therapy and for [ADDRESS_217120] dose of study drug. 
Exclusion Criteria: Subjects are excluded if any of the following criteria are met: 
1. Received any previous systemic treatment for cGVHD with the 
following exception: 
x Corticosteroids for cGVHD received within the 72 hours 
prior to signing the informed consent form. 
2. Inability t REHJLQDSUHGQLVRQHGRVHÂ•  mg/kg/d for the 
treatment of cGVHD. 
3. Presence of single-organ, genito-urinary involvement with 
cGVHD as the only manifestation of cGVHD. 
4. 5HFHLYHGDQ\LQYHVWLJDWLRQDODJHQWÂ”GD\VEHIRUH  
randomization. 
5. Received donor lymphocyte infusion (DLI) Â”[ADDRESS_217121]. http://www.hma.eu/fileadmin/dateien/Human_Medicines/01 
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 11 failure as defined by [CONTACT_115233]; or a history of myocardial infarction, unstable 
angina, or acute coronary syndrome within 6 months prior to 
randomization. 
7. Any uncontrolled active systemic infection or active infection requiring systemic treatment that was ongoing Â”GD\VEHIRUH  
randomization. This does not include secondary prophylaxis of well controlled fungal infections, ongoing treatment of controlled 
viral reactivations (eg, CMV), or treatment or prophylaxis of 
controlled low-grade central line infections (eg, Staphylococcus epi[INVESTIGATOR_77353]).  
8. Progressive underlying malignant disease or active 
post-transplant lymphoproliferative disease. 
9. History of other malignancy (not including the underlying 
malignancy that was the indication for transplant), with the following exceptions: 
x Malignancy treated with curative intent and with no evidence 
of active disease present for more than [ADDRESS_217122]. 
11. Known bleeding disorders (eg, von Willebrandâ€™s disease or 
hemophilia). 
12. History of stroke or intracranial hemorrhage within 6 months 
prior to randomization. 
13. Known history of human immunodeficiency virus (HIV). 
14. Subject with chronic liver disease with hepatic impairment per 
Child-Pugh classification Class C ( Appendix E ). Please note that 
acute liver dysfunction due to cGVHD is not applicable to the 
evaluation of Child-Pugh classification. 
15. Active hepatitis C virus (HCV) or hepatitis B virus (HBV). Subjects who are positive for hepatitis B core antibody or 
hepatitis B surface antigen or hepatitis C antibody must have a 
negative polymerase chain reaction (PCR) result before 
randomization. Those who are PCR positive will be excluded. 
16. Vaccinated with live, attenuated vaccines within 4 weeks of 
randomization. 
17. Major surgery within 4 weeks of randomization. 
18. Any life-threatening illness, medical condition, or organ system 
dysfunction that, in the investigatorâ€™s opi[INVESTIGATOR_1649], could compromise 
the subjectâ€™s safety or put the study outcomes at undue risk. 
19. Unable to swallow capsules or malabsorption syndrome, disease 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 12 significantly affecting gastrointestinal function, or resection of the 
stomach or small bowel, symptomatic inflammatory bowel 
disease or ulcerative colitis, or partial or complete bowel 
obstruction. 
20. Subjects requiring treatment with a strong CYP3A inducer are not eligible, unless a transition to an agent with less CYP3A induction is planned ( Appendix D ). 
21. Female subject who is pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within [ADDRESS_217123] 
dose of study drug. 
22. Unwilling or unable to participate in all required study 
evaluations and procedures. 
23. Unable to understand the purpose and risks of the study and to 
provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance 
with national and local subject privacy regulations). 
Study Treatment: 1:1 Randomization between Arm A and Arm B 
Arm A:  Oral ibrutinib 420 mg daily (3 capsules) in combination with 
oral prednisone starting at 1 mg/kg/day until unacceptable toxicity, 
progression of underlying disease, death, or the need for a new 
systemic treatment for progressive cGVHD. 
Arm B:  Oral matching placebo capsules daily (3 capsules) in 
combination with oral prednisone  starting at 1 mg/kg/day until 
unacceptable toxicity, progression of underlying disease, death, or the 
need for a new systemic treatment for progressive cGVHD. 
Concomitant Therapy:  Refer to Section 6  for information on concomitant therapy.  
Safety Plan:  The safety of this study will be monitored by [CONTACT_183944] (DMC) as outlined in the DMC charter and in 
accordance with the Sponsorâ€™s Pharmacovigilance procedures. 
Statistical Methods: All efficacy analyses will be performed using the intent-to-treat (ITT)  
population.  
Primary Efficacy Analysis: 
The primary efficacy endpoint of this study is the response rate at 
48 weeks (ie, the proportion of responders [CR or PR]). Response 
will be defined by [CONTACT_183942] 
(2014) and must occur: 
x In the absence of new systemic therapy for cGVHD 
x In the absence of progression of the underlying disease that was 
the indication for transplant, or death 
Response rates will be compared between the two treatment arms 
using the chi-square statistical test. 
Secondary Efficacy Analysis: 
x Response rate at 24 weeks (the proportion of responders [CR or 
PR]) as defined by [CONTACT_183945]Â® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 13 (2014) 
x Duration of response (DOR)  
x Steroid dose reduction to a level of less than 0.15 mg/kg/d at 
24 weeks: the proportion of subjects who have steroid dose reduced by 24 weeks will be compared between the two treatment 
arms 
x Time to withdrawal of all immunosuppressants (with the 
exception of ibrutinib/placebo) will be compared between the two 
treatment arms 
x Overall survival (OS): Overall survival will be compared between 
the two treatment arms using the log rank test 
x Improvement in Lee cGVHD symptom scale scores will be compared between the two treatment arms 
Safety Analysis: Safety data will be generated from the Safety Population (SP) which 
consists of all subjects randomized and receiving at least one dose of 
any study drug (ibrutinib or placebo). 
Detailed tabulations of safety data (adverse events, clinical laboratory 
tests and other safety endpoints) will be summarized by [CONTACT_183946].  
Interim Analysis: An interim review for futility will be performed for the first 50 
subjects who complete Week 25 visit or discontinue study drug before 
this time. 
Sample Size Determination: The null hypothesis is that the two treatment arms have the same 
response rate at 48 weeks and the alternative hypothesis is that the 
response rates of two arms are different. 
Assuming a response rate of 30% at 48 weeks for Arm B (placebo + 
prednisone), a sample size of [ADDRESS_217124] an 80% power to detect a 20% difference in the response rates at 
48 weeks between the 2 treatment arms (Arm A â€“ Arm B) at an alpha 
level of 5% (2-sided). 
The randomization between arms will be stratified according to: 
x Age group (12 to <22 \HDUVROGYVÂ• 22 years old) 
x NIH Global Severity grade (moderate vs. severe) 
x Ongoing use of systemic immunosuppressants that were initiated 
for either treatment of or prophylaxis for acute GVHD (Yes vs. 
No) 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217125] aspartate aminotransferase 
AUC area under the curve 
BAFF B-cell activating factor 
BCR B-cell receptor 
BTK Brutonâ€™s tyrosine kinase 
CFR US Code of Federal Regulations 
cGVHD chronic graft versus host disease 
CLL chronic lymphocytic leukemia 
CRF case report form 
CR complete response 
CTCAE v. 4.[ADDRESS_217126] 
HIV human immunodeficiency virus 
HPA Hypothalamic-pi[INVESTIGATOR_2117]-adrenal 
IB Investigatorâ€™s Brochure 
IC50 half maximal inhibitor concentration 
ICF Informed consent form 
ICH International Conference on Harmonization 
IEC Independent Ethics Committee 
IgM Immunoglobulin M 
IL Interleukin ILD interstitial lung disease 
INR international normalized ratio 
IRB Institutional Review Board 
ITK IL-2 inducible T-cell kinase 
ITT intention-to-treat IV Intravenous 
IWRS Interactive Web Response System 
KPS Karnofsky Performance Status 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 15 MCL mantle cell lymphoma  
mITT modified intention-to-treat 
MZL marginal zone lymphoma 
SP Safety population 
MTD maximum tolerated dose 
NCI National Cancer Institute 
NIH National Institutes of Health 
NRM non-relapse mortality 
OS overall survival 
PCI-[ZIP_CODE] ibrutinib or ImbruvicaÂ® 
PCR polymerase chain reaction 
PCYC Pharmacyclics LLC 
PD progressive disease 
PK pharmacokinetic 
PO oral 
PR partial response 
PTLD post-transplant lymphoproliferative disease 
PT prothrombin time 
QD daily  
QOD every other day 
QTc corrected QT interval 
REB Research Ethics Board 
SAE serious adverse event 
SCARs severe cutaneous adverse reactions 
SD stable disease 
SF-36 36-Item Short Form Health Survey 
SJS Stevens - Johnson syndrome 
t1/2 half life 
TEAE(s) treatment-emergent adverse event(s) 
TCR T-cell receptor 
TLS tumor lysis syndrome 
Tmax median time to maximum plasma concentration 
ULN upper limit of normal 
USPI [INVESTIGATOR_183894]Ã¶mâ€™s macroglobulinemia 
  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 16 1. BACKGROUND 
1.1. Disease/Histology  
1.1.1. Disease Background 
Since its first report in 1957, allogeneic hemat opoietic cell transplant (HCT) has become a 
standard therapy for many hematologic malignanc ies and hematopoi etic progenitor cell disorders 
(Thomas 1957 ). Hematopoietic cell transplant can cure  patients with chemotherapy resistant 
malignancies through graft versus tumor (GVT) effects generated by [CONTACT_183947]â€™s immune system 
against the recipi[INVESTIGATOR_841]â€™s tumor ( Appelbaum 2001 ). However, just as the donorâ€™s immune system 
can sense and attack the recipi[INVESTIGATOR_841]â€™s malignant cells, so can it sense and attack the recipi[INVESTIGATOR_841]â€™s normal tissues resulting in graft versus host di sease (GVHD). In the U.S., approximately 8,000 
allogeneic HCTs are now performed each year ( Pasquini 2015 ). Roughly 35% of patients who 
have undergone HCT will develop cGVHD that requires systemic treatment ( Flowers 2011). The 
prevalence of cGVHD is increasing due to both the increased use of allogene ic transplantation in 
older adults and the use of peripheral stem cells as a graft source. Chronic GVHD is a serious 
and life threatening impediment to the otherwise curative potential of HCT ( Pi[INVESTIGATOR_43221] [ADDRESS_217127] 2006 and Lee 2003 ) and it is a leading cause of non-relapse mortality (NRM) 
(Lee 2008 ). Risk factors for developi[INVESTIGATOR_183895], older age, use of 
peripheral blood stem cells, use of  unrelated and mismatched donors, and lack of T-cell depletion 
(Lee 2008 ). 
In the past, timing of manifestations of GVHD were  used to classify GVHD into two subsets, 
acute GVHD classified as occurring within [ADDRESS_217128] ( Filipovich 2005 ). In 2005 the National Institutes of 
Health (NIH) sponsored a consensus development conference that proposed new criteria for 
diagnosis and classification of cGVHD for clinical trials ( Filipovich 2005 ). The consensus met 
again in 2014 and proposed minor changes to the diagnostic criteria (Jagasia 2015 ). The 
published criteria for diagnosis emphasize the di stinction between acute and chronic GVHD as 
different subsets of GVHD that can be distinguished by [CONTACT_183948]. The diagnosis of cGVHD is primarily c linical and requires at least one diagnostic sign 
in a target organ per NIH criteria (ie, a sign found only in cGVHD) or at least one distinctive 
sign (ie, a sign highly suggestive of cGVHD) in  combination with some other laboratory, biopsy, 
or other test confirmation in the same or another organ. The diagnostic cGVHD findings include collagen-vascular changes involving the skin, mouth, genitalia, gastrointe stinal tract, lung, 
muscle fascia, and joints ( Jagasia 2015 ) (Appendix M ). Pathologically, cGVHD is characterized 
by [CONTACT_183949] ( Shulman 2006).  
Pathogenesis of Chronic Graft Versus Host Disease 
The immunopathology underlying development of cGVHD can be quite variable and is not entirely characterized. Recent information implicates B cells as well as T cells in the generation 
of cGVHD ( Sarantopoulos 2015, Allen 2014, Flynn 2014 and Johnston 2014). T cells have long 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 17 been known to be critically important in the development of cGVHD. Higher rates of cGVHD 
are seen in recipi[INVESTIGATOR_183896]-stimulating factor mobilized peripheral blood grafts compared 
with marrow grafts and in patients who receive a higher T cell dose ( Anasetti 2011 ). In vivo 
T cell depletion with anti-thymocyte globulin or alemtuzumab can reduce the incidence of 
cGVHD, but at the cost of higher rates of vi ral or opportunistic inf ections and relapse of 
underlying disease ( Hale 2012, Perez-Simon 2002 ). Alloreactive T helper cells, including Th1, 
Th2, Th17, and T follicular helper cells, produce  effector cytokines resulting in antibody 
deposition, tissue fibrosis, and autoimmunity. 
More recently, alloreactive B cells have been implicated in the development of cGVHD 
(Sarantopoulos 2015, Allen 2014 , Flynn 2014, Johnston 2014, Miklos 2005 and Miklos 2004 ). 
In addition to the production of alloantibodies, B cells contribute to the immune response via 
antibody-independent processes, such as an tigen presentation, cytokine and chemokine 
production, and immunoregulatory function ( Sahaf 2013). Following activation via the B-cell 
receptor (BCR) signaling pathways, B cells become potent antigen-presenting cells. Activated 
B cells produce a variety of inflammatory cytoki nes, and antigen presentation by [CONTACT_183950] 
B cells is critical in autoimmune disorders (Shimabukuro-Vornhagen 2009 ). Dysfunctional 
B cells have been identified in cGVHD, where patients have a relatively higher number of 
activated memory B cells, higher levels of B-cell-activating factor (BAFF) of the tumor necrosis family, and donor-derived alloantibodies ( Sarantopoulos 2009). 
1.1.2. Current Treatment Options 
Available therapy for cGVHD is primarily br oad-spectrum immunosuppressants which increase 
the risk of infections and tumor relapse by [CONTACT_183951] (Holler 2007 ). The initial 
and current standard of care treatment for cGVH D is corticosteroids. However, more than 50% 
of the patients eventually relapse or become refractory, requiring second-line treatment, for 
which there is no standard of care. Recently, ibrutinib received approval in the [LOCATION_002] for 
the treatment of adult patients with cGVHD after failure of one or more lines of systemic 
therapy. 
Treatment with immunosuppre ssants is typi[INVESTIGATOR_183897] a median duration of 2 to 3 years, 
further contributing to morbidity ( Syrjala 2012 ). During that time patients are likely to 
experience some or all of the side effects of  corticosteroids which include more frequent 
infections, hypertension, hyperglycemia, decrease in bone density, avascular necrosis, adrenal 
insufficiency, cataracts and disturbed sleep patterns ( Sullivan 1988, Rayos [Prednisone] 
USPI 2013 ). Because of the frequent morbidity associated with prolonged corticosteroid use, 
many other immunosuppressant agents have been investigated in cGVHD, both in the front line 
and second line setting. Several c ontrolled, phase [ADDRESS_217129] been added 
on to corticosteroid therapy were all unsuccessful in providing benefit despi[INVESTIGATOR_183898] ( Gilman 2012 , Martin 2009 , Koc 2002 , Arora 2001 , K
oc 2000 , and 
Sullivan 1988). An analysis of clinical trial quality measures in 60 trials in cGVHD primarily 
conducted before the NIH sta ndardized response criteria ( Pavletic 2006 ) were developed, 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 18 revealed that poor study design (eg, lack of ri gorous entry criteria, organ response criteria and 
overall response criteria) likely biased efficacy in the early phase trials ( Martin 2011) thereby 
[CONTACT_183952]. Agents such as 
cyclosporine, tacrolimus, sirolimus, and/or mycophenolate mofetil are often added to 
corticosteroid therapy in both frontline and second line settings despi[INVESTIGATOR_183899]. 
There is a lack of standard of care and high unmet need for new therapeutic options to effectively 
suppress immune and fibrotic cas cades while preserving GVT a nd immunity against infection.  
While limited progress related to prevention or treatment of cGVHD has been made, the development of the NIH Consensus Criteria for grading and staging of cGVHD represents a 
significant advancement, providing a clinically us eful disease burden measure for use in clinical 
trials ( Jagasia 2015 ). In addition, the NIH Consensus Response Criteria have been shown to 
correlate with clinical outcomes ( Olivieri 2013 , Jacobsohn 2012 ). 
1.2. Ibrutinib Overview  
Ibrutinib (I
MBRUVICAÂ®) is a first-in-class, potent, oral ly administered, covalently binding 
inhibitor of Brutonâ€™s tyrosine kinase (BTK) co-developed by [CONTACT_183953] & Development LLC for the treatment of B-cell malignancies and cGVHD. 
Ibrutinib has been approved in many regions, in cluding the US and EU, fo r indications including 
treatment of patients with mantle cell lymphoma (MCL) who have received at least 1 prior 
therapy, patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma 
(SLL), including CLL/SLL with a deletion of the short arm of chromosome 17 (del17p), patients 
with WaldenstrÃ¶mâ€™s macroglobulinemia (WM), Marginal Zone Lymphoma (MZL) who require 
systemic therapy and have received at leas t one prior anti-CD20-base d therapy, and cGVHD 
after failure of one or more lines  of systemic therapy. For the most up to date and comprehensive 
nonclinical and clinical information regarding ibrutinib background, safety, efficacy, in vitro and in vivo preclinical activity, and toxicology of ibru tinib, always refer to the latest version of the 
ibrutinib Investigator's Brochure (IB) and/or the applicable regional labeling information.   
1.2.1. Summary of Nonclinical Data  
[IP_ADDRESS]. Pharmacology  
Ibrutinib was designed as a selective and covalent inhibitor of the BTK ( Pan 2007 ). In vitro, 
ibrutinib is a potent inhibitor of BTK activity (IC
50 = 0.39 nM). The irreversible binding of 
ibrutinib to cysteine-481 in the active site of BT K results in sustained inhibition of BTK catalytic 
activity and enhanced selectivity over other kinases that do not cont ain a cysteine at this position. 
When added directly to human whole blood, ibrutin ib inhibits signal transduction from the BCR 
and blocks primary B- cell activation (IC 50 = 80 nM) as assayed by [CONTACT_14181]-IgM stimulation followed 
by [CONTACT_398]69 expression ( Herman 2011 ). In addition to BTK activity, ibrutinib inhibits ITK activity 
with a biochemical IC 50 of 26.9 nM. Ibrutinib also blocks T cell receptor-induced IL-2 secretion 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 19 by a T cell line (Jurkat cells) with an EC 50 of 200 nM. In CLL patients receiving ibrutinib, 
binding to ITK also has been demonstrated ( Dubovsky 2013). 
For more detailed and comprehensive information regarding nonclinical pharmacology and 
toxicology, please refer to the current IB. 
[IP_ADDRESS]. Safety Pharmacology and Toxicology 
No treatment-related effects were observed in the central nervous system or respi[INVESTIGATOR_183900]. Further, no treatment-re lated corrected QT interval (QTc) prolongation 
effect was observed at any tested dose in a card iovascular study using telemetry-monitored dogs. 
Based on data from rat and dog including genera l toxicity studies up to [ADDRESS_217130] potential for human toxicity with ibrutin ib is predicted to be in lymphoid tissues 
(lymphoid depletion) and the gastrointestinal tract (soft feces/diarrhea with or without 
inflammation). Additional toxicity findings seen  in only one species with no observed human 
correlate in clinical studies to date include pancreatic acinar cell atrophy (rat), minimally 
decreased trabecular and cortical bone (rat) and co rneal dystrophy (dog). In studies in pregnant 
rats and rabbits, ibrutinib administration was associated with malformations (teratogenicity) at ibrutinib doses that result in approximate ly 14 and 2 times the exposure (area under the 
concentration-time curve [AUC]) in  patients administered the dose of [ADDRESS_217131] comprehensive clinical information regarding ibrutinib, please refer to the current version of the IB. 
[IP_ADDRESS]. Pharmacokinetics and Product Metabolism  
Following oral administration of ibrutinib at doses ranging from 420 to 840 mg/day, exposure to ibrutinib increased proportionally to doses increased with substantial intersubject variability. The 
mean half-life (t
1/2) of ibrutinib ranged from 4 to 13 hours, with a median time to maximum 
plasma concentration (T max) of 2 hours. Taking into account the approximate doubling in mean 
systemic exposure when dosed with food and the fa vorable safety profile, ibrutinib can be dosed 
with or without food. Ibrutinib is extensiv ely metabolized primarily by [CONTACT_9058] 
P450 (CYP) 3A4 enzymes. The on-target effect s of metabolite PCI-[ZIP_CODE] are not considered 
clinically relevant. Steady-state exposure of ibrutinib and PCI-[ZIP_CODE] was less than 2-fold of 
single dose exposure. Less than 1% of ibrutinib is excreted renally. Ibrutinib exposure is not 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 20 altered in patients with creatinine clearance (CrCl) >30 mL/min. Patients with severe renal 
impairment or patients on dialysis have not been  studied. Following single dose administration, 
the AUC of ibrutinib increased 2.7-, 8.2- and 9.8-fo ld in subjects with mild (Child-Pugh class A), 
moderate (Child-Pugh class B), a nd severe (Child-Pugh class C) he patic impairment compared to 
subjects with normal liver function. A higher prop ortion of Grade 3 or higher adverse reactions 
were reported in patients with B-cell malignancies (CLL, MCL and WM) with mild hepatic 
impairment based on NCI organ dysfunction wo rking group (NCI-ODWG) criteria for hepatic 
dysfunction compared to patient s with normal hepatic function. In the Phase 2 study in subjects 
with cGVHD, there were no differences in ib rutinib exposure between subjects with normal 
(n=29) and mild hepatic impairment based on baseline liver function test per NCI criteria (n=13).  
For the most comprehensive information regarding pharmacokinetics (PK) and product 
metabolism, please refer to the current version of the IB. 
1.2.3. Summary of Clinical Safety  
A brief summary of safety data  from monotherapy studies, comb ination therapy studies, and a 
cGVHD study is provided below.  
[IP_ADDRESS]. Monotherapy Studies  
Pooled safety data from a tota l of [ADDRESS_217132] completed primary analysis or final an alysis as of the 31 May 2016 cutoff date for the 
current Investigatorâ€™s Brochure update in B-cell malignancies are summarized below.  
The most frequently reported treatment-emergent adverse events (TEAEs) in subjects receiving 
ibrutinib as monotherapy (N=1318): 
Most frequently reported 
TEAEs Â•15% a Most frequently reported Grade 3 or 4 TEAEs Â•3% 
b  Most frequently reported Serious TEAEs Â•2% 
c 
Diarrhea Neutropenia Pneumonia 
Fatigue Pneumonia Atrial fibrillation 
Nausea Thrombocytopenia Febrile neutropenia 
Cough Anemia Pyrexia 
Pyrexia Hypertension  
Anemia Diarrhea  
Neutropenia  Atrial Fibrillation  
Upper respi[INVESTIGATOR_183901]    
a Source is Table 6 of IB (v10) , b Source is Table 8 of IB (v10) , c Source is Table 9 of IB (v10) . 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 21 [IP_ADDRESS]. Combination Studies 
Pooled safety data from a total of 423 subjects treated with various  therapi[INVESTIGATOR_14129] 4 studies conducted in subjects w ith B-cell malignancies are briefly summarized 
below. Therapi[INVESTIGATOR_14130], included BR (bendamustine 
and rituximab), FCR (fludara bine, cyclophosphamide, and r ituximab), ofatumumab, and 
R-CHOP (rituximab, cyclophosphamide, doxorubi cin, vincristine, and prednisone). 
The most frequently reported TEAEs in subjects receiving ibrutinib in combination therapy 
(N=423): 
Most frequently reported 
TEAEs Â•0%a Most frequently reported Grade 3 or 4 TEAEs Â•%
b  Most frequently reported Serious TEAEs Â• %
c  
Neutropenia Neutropenia Pneumonia 
Diarrhea Thrombocytopenia Febrile neutropenia 
Nausea Febrile neutropenia Atrial fibrillation 
Thrombocytopenia Pneumonia Pyrexia 
Fatigue Neutrophil count decreased Cellulitis 
Anemia Anemia  
Pyrexia Fatigue  
 Hypertension  
 Diarrhea  
a Source is Table 10 of IB (v10), b Source is Table 12 of IB (v10), c Source is Table 13 of IB (v10) . 
[IP_ADDRESS]. Chronic GVHD Study 
Safety data from the 42 subjects enrolled in the PCYC-1129-CA study demonstrated that 100% 
of subjects have experienced a treatment-emergen t adverse event (TEAE) with a total of 73.8% 
of subjects reported Grade 3 or higher AEs. Fifty-two percent (52.4%) of subjects reported 
serious adverse events (SAEs). The most fre quent TEAEs and SAEs are summarized below.  
Most frequently reported TEAEs in subjects receiving ibrutinib for cGVHD (N=42): 
Most frequently reported 
TEAEs > 20% Most frequently reported  Grade 3 or 4 TEAEs > 10% Serious TEAEs occurred 
in > [ADDRESS_217133] 
Fatigue Fatigue Cellulitis 
Diarrhea Pneumonia Headache  
Muscle spasms  Pneumonia  
Nausea    Pyrexia 
Increased tendency to bruise  Septic shock 
Thirty subjects (71.4%) were taking moderate or strong CYP3A inhibitors during the study with 
9.5% of subjects taking posacona zole, 42.9% taking fluconazole, and 14.3% taking voriconazole. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 22 Concomitant use of moderate and strong CYP3A inhibitors resulted in higher ibrutinib exposure 
but there was no association between concurrent  CYP3A inhibitor use and dose reductions or 
discontinuations or with TEAEs leading to dose reductions or discontinuations. 
1.2.4. Risks 
[IP_ADDRESS]. Atrial Fibrillation 
Atrial fibrillation and atrial flutter have been reported in subjects treated with ibrutinib, 
particularly in subjects with car diac risk factors, hypertension, acu te infections, and a previous 
history of atrial fibrillation. Subjects who develop arrhythmic  symptoms (eg, palpi[INVESTIGATOR_814], 
lightheadedness) or new onset dyspnea should be ev aluated clinically, and if indicated, have an 
ECG performed. For atrial fibrillation which persists, consider the risks and benefits of ibrutinib treatment and follow the protocol dose modification guidelines (see Section [IP_ADDRESS] ). 
[IP_ADDRESS]. Bleeding-related Events 
There have been reports of hemorrhagic events in  subjects treated with ibrutinib, both with and 
without thrombocytopenia. These include minor hemorrhagic events such as contusion, epi[INVESTIGATOR_3940], 
and petechiae; and major hemorrhagic events, some fatal, including gastrointestinal bleeding, 
subdural intracranial hemorrhage, and hematuria. Use of ibrutinib in subjects requiring other 
anticoagulants or medications that inhibit platel et function may increase the risk of bleeding. 
Subjects with congenital bleeding diat hesis have not been studied. See Section 6.2.3  for guidance 
on concomitant use of anticoagulants, antip latelet therapy and/or supplements. See Section 6.4 
for guidance on ibrutinib management with surger ies or procedures. In an in vitro platelet 
function study, inhibitory effects of ibrutinib  on collagen induced platelet aggregation were 
observed, refer to Section 6.2.3. 
[IP_ADDRESS]. Cytopenias 
Treatment-emergent Grade 3 or 4 cytopenias (neu tropenia, thrombocytopenia, and anemia) were 
reported in subjects treated with ibrutinib. Subject s should be monitored for fever, weakness, or 
easy bruising and/or bleeding. 
[IP_ADDRESS]. Diarrhea 
Diarrhea is the most frequently reported non-he matologic AE with ibrutinib monotherapy and 
combination therapy. Other frequently reported gastrointestinal events include nausea, vomiting, 
and constipation. These events are rarely seve re. Should symptoms be severe or prolonged 
follow the protocol dose m odification guidelines (see Section [IP_ADDRESS]).  
[IP_ADDRESS]. Infections 
Infections (including sepsis, bacterial, viral, aspergillus or other fungal infections) were observed 
in subjects treated with ibrutinib therapy. Some of  these reported infections have been associated 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217134] of care in subjects 
who are at increased risk for opportunistic infections (see Section 6.1 ). Although causality has 
not been established, cases of progressive multif ocal leukoencephalopathy (PML) have occurred 
in subjects treated with ibrutinib. Subjects s hould be monitored for symptoms (fever, chills, 
weakness, confusion) and appropriate therapy should be instituted as indicated.  
[IP_ADDRESS]. Interstitial Lung Disease (ILD) 
Cases of interstitial lung disease (ILD) have been reported in subjects treated with ibrutinib. 
Monitor subjects for pulmonary symptoms indica tive of ILD. Should symptoms develop follow 
the protocol dose modifi cation guidelines (see Section [IP_ADDRESS] ). 
[IP_ADDRESS]. Non-melanoma Skin Cancer 
Non-melanoma skin cancers have occurred in s ubjects treated with ibrutinib. Monitor subjects 
for the appearance of non-melanoma skin cancer. 
[IP_ADDRESS]. Rash 
Rash has been commonly reported in subjects treated with either single agent ibrutinib or in 
combination with chemotherapy. Most rashes were mild to moderate in severity. Isolated cases 
of severe cutaneous adverse reactions (SCA Rs) including Stevens - Johnson syndrome (SJS) 
have been reported in subjects treated with ib rutinib. Subjects should be  closely monitored for 
signs and symptoms suggestive of SCAR including  SJS. Subjects receiving ibrutinib should be 
observed closely for rashes and treated symptoma tically, including interruption of the suspected 
agent as appropriate. In addition, hypersensitivit y-related events includi ng erythema, urticaria, 
and angioedema have been reported. 
[IP_ADDRESS]. Hypertension 
Hypertension has been commonly reported in subj ects treated with ibrutinib. Monitor subjects 
for new onset of hypertension or hypertension th at is not adequately controlled after starting 
ibrutinib. Adjust existing anti-hypertensive medications and/or initiate anti-hypertensive 
treatment as appropriate. 
1.2.5. Summary of Clinical Data in Chronic GVHD 
A Phase 1b/2 study (PCYC-1129-CA) to evaluate the safety and efficacy of ibrutinib treatment 
in subjects with cGVHD who had failed steroi d therapy was initiated in June 2014. The NIH 
Consensus Panel Response Assessment [ADDRESS_217135] one dose of study drug in 
the study. The median age is 56 years (19-74 years) with a median duration of GVHD of 
13.[ADDRESS_217136] response assessment. Of the 42 subjects w ith response assessments or who discontinued 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 24 ibrutinib prior to response assessment, 28 subjects are responders (ORR=67%) based on NIH 
response criteria. Best responses include 9 CRs, 19 PRs, 7 stable disease (SD), 2 progressive 
disease (PD), and [ADDRESS_217137] baseline 
efficacy assessment. Twenty of the 28 responders  (71%) achieved a sust ained response for at 
least 20 weeks. Median corticosteroid dose in responding subjects was 0.29 mg/kg/d at baseline, 
0.24 mg/kg/d at Week 12, 0.19 mg/kg/d at Week 24, 0.18 mg/kg/d at Week 36, and 0.13 mg/kg/d at Week 48. Five subjects were able to disconti nue steroids. Overall response rate results were 
supported by [CONTACT_183954]-repo rted symptom bother which showed at least a 
7-point decrease in Lee Symptom Scale overall su mmary score in 24% (10/ 42) of patients on at 
least 2 consecutive visits.  
These efficacy results are consistent with a response rate and durability that is considered 
clinically compelling in this high-risk population and with an acceptable safety profile. Based on 
data from the PCYC-1129 study the US FDA ap proved ibrutinib for the treatment of adult 
patients with cGVHD after failure of one or more lines of systemic therapy. 
1.3. Prednisone  
Prednisone is a glucocorticoid. Glucocorticoids are adrenocortical  steroids (corticosteroids), both 
naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. The 
chemical name [CONTACT_183989]- 1,4-diene-3,11,20-trione m onohydrate,17,21-dihydroxy. 
Naturally occurring glucocorticoids (hydrocor tisone and cortisone), which also have salt-
retaining properties, are used as replacement ther apy in adrenocortical deficiency states. Their 
synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, 
they modify the bodyâ€™s immune responses to diverse stimuli. 
1.3.1. Summary of Clinical Data 
Prednisone is a corticosteroid indicated in the following conditions: 
x As an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, 
gastrointestinal, hematologic, ophthalmologi c, nervous system, renal, respi[INVESTIGATOR_696], 
rheumatologic, specific infectious diseases  or conditions and organ transplantation 
x For the treatment of cert ain endocrine conditions 
x For palliating of certai n malignant conditions 
1.3.2. Summary of Clinical Safety 
Alterations in Endocrine Function  
Hypothalamic-pi[INVESTIGATOR_2117]-adrenal (HPA) axis suppression, Cushingâ€™s syndrome, and 
hyperglycemia. Monitor patients for these conditions with chronic use. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217138] 
for months after discontinuation of therapy; theref ore, in any situation of stress occurring during 
that period, hormone therapy should be reinstitute d. If the patient is receiving corticosteroids 
already, dosage may have to be increased. 
Since mineralocorticoid secretion may be impaire d, salt and/or a mineralocorticoid should be 
administered concurrently. Minera locorticoid supplementation is of particular importance in 
infancy. 
Metabolic clearance of corticosteroids is decr eased in hypothyroid patients and increased in 
hyperthyroid patients. Changes in thyroid status  of the patient may necessitate adjustment in 
dosage.  
Increased Risks Related to Infection  
Corticosteroids may increase the risks related to infections with any pathogen, including viral, 
bacterial, fungal, protozoan, or helminthic infections. The degree to which the dose, route and 
duration of corticosteroid administration correlates with the specific risks of infection is not well 
characterized, however, with increasing doses of corticosteroids, the rate of occurrence of 
infectious complications increases.  
Corticosteroids may mask some signs of infection and may reduce resistance to new infections.  
Corticosteroids may exacerbate infections and increase risk of disseminated infections.  
The use of prednisone in active tuberculosis should be restricted to those cases of fulminating or 
disseminated tuberculosis in whic h the corticosteroid is used for management of the disease in 
conjunction with an appropriate  anti-tuberculous regimen.  
Chickenpox and measles can have a more serious or  even fatal course in non-immune children or 
adults on corticosteroids. In children or adults who have not had these di seases, particular care 
should be taken to avoid exposure. If a patient is exposed to chickenpox, prophylaxis with varicella zoster immune globulin (V ZIG) may be indicated. If pa tient is exposed to measles, 
prophylaxis with pooled intramuscular immunogl obulin (IG) may be indicated. If chickenpox 
develops, treatment with antiviral agents may be considered. 
Corticosteroids should be used with great care in patients with known or suspected Strongyloides 
(threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead 
to Strongyloides hyperinfection and dissemina tion with widespread larval migration, often 
accompanied by [CONTACT_183955]-negative septicemia.  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 26 Corticosteroids may exacerbate systemic fungal infections and therefore should not be used in 
the presence of such infections unless they  are needed to control drug reactions.  
Corticosteroids may increase risk of reactiv ation or exacerbation of  latent infection.  
If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close 
observation is necessary as reactivation of the disease may occur. During prolonged 
corticosteroid therapy, these patients should receive chemoprophylaxis.  
Corticosteroids may activate latent amebiasis. Therefore, it is recommended that latent amebiasis 
or active amebiasis be ruled out before initiating corticosteroid therapy in any patient who has 
spent time in the tropi[INVESTIGATOR_183902].  
Corticosteroids should not be used in cerebral malaria.  
Alterations in Cardiovascular/Renal Function  
Corticosteroids can cause elevation of blood pres sure, salt, and water retention, and increased 
excretion of potassium and calcium. These effects are less likely to occur with the synthetic 
derivatives except when used in large dos es. Dietary salt restriction and potassium 
supplementation may be necessary. These agents should be used with caution in patients with 
congestive heart failure, hypertension, or renal insufficiency.  
Literature reports suggest an apparent association between us e of corticosteroids and left 
ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with 
corticosteroids should be used with great caution in these patients. 
Use in Patients with Gastrointestinal Disorders  
There is an increased risk of gastrointestinal perforation in patients with certain GI disorders. 
Signs of GI perforation, such as peritoneal irritation may be masked in patients receiving 
corticosteroids. 
Corticosteroids should be used with caution if there is a probability of impending perforation, 
abscess, or other pyogenic infections; diverticulitis; fresh intestinal anastomoses; and active or 
latent peptic ulcer. 
Behavioral and Mood  Disturbances  
Corticosteroids use may be associated with central nervous system effects ranging from 
euphoria, insomnia, mood swings, personality change s, and severe depression, to frank psychotic 
manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated 
by [CONTACT_13216].  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217139] 
on calcium regulation (ie, decreasing absorption and increasing excretion) and inhibition of 
osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to 
an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of 
bone growth in children and adoles cents and the development of osteoporosis at any age. Special 
consideration should be given to  patients at increased risk of  osteoporosis (ie, postmenopausal 
women) before initiating corticosteroid therapy and bone dens ity should be monitored in patients 
on long term corticosteroid therapy. 
Ophthalmic Effects  
Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with 
possible damage to the optic nerves, and may enhance the establishment of secondary ocular 
infections due to fungi or viruses.  
The use of oral corticosteroids is not recommended in the treatment of optic neuritis and may 
lead to an increase in the risk of new epi[INVESTIGATOR_1841].  
Intraocular pressure may become elevated in so me individuals. If corticosteroid therapy is 
continued for more than 6 weeks, intraocular pressure should be monitored.  Corticosteroids should be used cautiously in pa tients with ocular herp es simplex because of 
possible corneal perforation. Corticosteroids should not be used in active ocular herpes simplex.  Vaccination 
Administration of live or live, attenuated vaccines is contraindicated in patients receiving 
immunosuppressive doses of corticos teroids. Killed or inactivated vaccines may be administered; 
however, the response to such vaccines cannot be  predicted. Immunization procedures may be 
undertaken in patients who are receiving corticosteroids as replacement therapy, eg, for 
Addisonâ€™s disease.  
While on corticosteroid therap y, patients should not be vaccinated against smallpox. Other 
immunization procedures should not be undertaken  in patients who are on corticosteroids, 
especially on high dose, because of possible hazards of neurological complications and a lack of 
antibody response.  
Effect on Growth and Development 
Long-term use of corticosteroids can have negative effects on growth and development in 
children. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217140] often 
occurring in patients with disorders of neuromuscu lar transmission (eg, myasthenia gravis), or in 
patients receiving concomitant therapy with neuromuscular blocking drugs (eg, pancuronium). 
This acute myopathy is generaliz ed, may involve ocular and resp iratory muscles, and may result 
in quadriparesis. Elevation of cr eatine kinase may occur. Clinical  improvement or recovery after 
stoppi[INVESTIGATOR_80563]. 
Kaposiâ€™s Sarcoma  
Kaposiâ€™s sarcoma has been reported to occur in pa tients receiving corticosteroid therapy, most 
often for chronic conditions. Discontinuation of  corticosteroids may result in clinical 
improvement. 1.3.3. Summary of Clinical Data in Ch ronic Graft versus Host Disease 
Corticosteroids have been the b ackbone of treatment of cGVHD fo r more than 3 decades despi[INVESTIGATOR_183903] ( Flowers 2015 , Wolff 2011 , Dignan 2012 ). While 
effective, prolonged administration of systemic corticosteroids results in substantial morbidity 
including hypertension, bone loss, weight gain, diabetes, cataracts, and myopathy as well as 
increasing the risk for underlying malignancy. The administration of alternate day steroids is often attempted to mitigate the risk of these toxicities. In addition, rapid corticosteroid taper and 
discontinuation is preferred in cGVHD. 
1.4. Study Rationale  
While corticosteroids are effective in some patie nts, until the approval of ibrutinib in August 
2017 for adult patients with cGHVD afte r failure of one or more lines of systemic therapy, there 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217141] clinical 
activity with high response rate by [CONTACT_183956]. 
These data also support the continued clinical evaluation of ibrutinib in combination with 
prednisone as a treatment option for patients with new onset cGVHD. 
2. STUDY OBJECTIVES 
2.1. Primary Objective 
To evaluate the efficacy of ibrutinib in combination with prednisone (Arm A) versus placebo in 
combination with prednisone (Arm B) based on the response rate at 48 weeks (the proportion of 
responders [CR or PR]) as determined by [CONTACT_183957] H Consensus Development Project Criteria in 
subjects with new onset mode rate to severe cGVHD ( Lee 2015 , Jagasia 2015 ). 
2.2. Secondary Objective(s) 
x To compare the two treatment arms in terms of the following: 
Efficacy 
x Response rate at 24 weeks (the proportion of re sponders [CR or PR]) as defined by [CONTACT_183958] (2014) 
x Duration of response (DOR) 
x Proportion of subjects obtaining a steroid dos e level less than 0.15 mg/kg/d at 24 weeks 
x Time to withdrawal of al l immunosuppressants (with the exception of ibrutinib/placebo) 
x Overall survival (OS) 
x Lee cGVHD symptom scale improvement 
Safety 
x Safety and tolerability  
x Differences in steroid-related morbidities (eg, hyperglycemia, hypertension)  
2.3. Exploratory Objective(s)  
x Pharmacokinetics of ibrutinib when administered in combination with prednisone in 
subjects with cGVHD including adolescent subjects 
x Pharmacodynamic characteristics of ibrutinib  (including BTK and ITK occupancy) in 
subjects with cGVHD 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217142] Crite ria, will be randomized in a 1:1 ratio to 
receive either ibrutinib in combination with prednisone (Arm A) or placebo in combination with 
prednisone (Arm B). It is expected that a minimum of 6 subjects in the adolescent group ( Â•12 
and <  22 years of age) will be enrolled. 
Treatment with ibrutinib/place bo will be administered continuously until unacceptable toxicity, 
progression of the underlying disease, death, or  the start of a new systemic treatment for 
cGVHD. Progression of the underlying disease will be defined using standard consensus criteria 
for the individual malignancy. 
Corticosteroid therapy will be ta pered as per a standard taper re gimen with the goal of reducing 
exposure to high-moderate dose corticosteroids as  quickly as possible according to clinical 
severity of cGVHD. A standard corticosteroid taper schedule is provided in the protocol as 
guidance to clinicians ( Table 4 ). 
The primary endpoint is the response rate at [ADDRESS_217143] Cr iteria (2014) and must occur: 
x In the absence of new therapy for cGVHD 
x In the absence of progression of the underl ying disease that was the indication for 
transplant, or PTLD, or death 
Secondary endpoints will assess for additional clinical  benefit including Week-24 response, 
duration of response (DOR), corticosteroid  dose reduction, time to withdrawal of all 
immunosuppressants, OS, and Lee cGVHD symptom scale. Corticostero id reduction will be 
determined by a proportion of patients who are on < 0.15 mg/kg of prednisone at week 24, to 
allow for variations in corticosteroid taper that occur in practice, while at the same time reaching a dose that minimizes the toxicity associated with steroids. 
The randomization between arms will be stratified according to: 
x Age group (12 to <22 \HDUVROGYVÂ•22 years old) 
x NIH Global Severity grad e (moderate vs. severe) 
x Ongoing use of systemic immunosuppressants that  were initiated for e ither treatment of 
or prophylaxis for acute GVHD (Yes vs. No) 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 31 The rationale for the study concept is provided in Section 1.4 . 
3.1.1. Study Schema 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Screening Phase 
(within [ADDRESS_217144] start ibrutinib/placebo within 72 hours (3 days) after randomization 
Treatment Arm A  
  
Prednisone 1 mg/kg/d 
 
Ibrutinib [ADDRESS_217145] begins 
another systemic treatment for cGVHD or unacceptable 
toxicity Treatment Arm B 
  
Prednisone 1 mg/kg/d 
 
Placebo oral once daily continuously 
starting on Week [ADDRESS_217146] begins 
another systemic treatment for cGVHD or unacceptable 
toxicity 
 Double-Blind Treatment Phase  
Ibrutinib/Placebo Discontinuation 
Complete End-of-Treatment Visit 
Follow-up Phase  
(up to 60 months after randomization) 
Prior to cGVHD Progression (if applicable):  
Continue cGVHD evaluations 
Follow-up for survival status, subsequent therapi[INVESTIGATOR_183904]:  
Follow-up for survival status, subsequent therapi[INVESTIGATOR_183905]Â® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217147] Criteria (2014, see Appendix M , Appendix N , and Appendix O ). 
2. History of an allogeneic he matopoietic ce ll transplant. 
3. Need for systemic treatment with corticosteroids for cGVHD. 
4. No previous systemic treatment for cGVHD (i ncluding extracorporeal photopheresis [ECP]). 
5. Participants may be receiving other immunosuppre ssants for the prophylaxis or treatment of 
acute GVHD but if the subject is receiving pre dnisone for prophylaxis or treatment of acute 
GVHD it must be at or below 0.5 mg/kg/d.  
6. Participants may have received pre-transplant  BTK inhibitors for other reasons besides 
cGVHD such as for the treatment of leukemia or lymphoma, but must not have received a 
BTK inhibitor since the time of transplant. 
Demographic 
7. $JHÂ• 12 years old. 
8. Karnofsky or Lansky (subjects <1\HDUVSHUIRUPDQFHVWDWXVÂ• 60. 
Laboratory 
9. Adequate renal function defined as estimated Creatinine Clearance Â•30 mL/min (Cockcroft-
Gault formula) 
10. Adequate hepatic func tion as defined by: 
x Total bilirubin of Â” 1.[ADDRESS_217148] (unless of non-hepatic origin or due to Gilbert's 
Syndrome) or 
x Total bilirubin of > 1.[ADDRESS_217149] if due to GVHD 
11. Adequate hematological  function defined as: 
x $EVROXWHQHXWURSKLOFRXQWÂ•[9/L and off growth factor support for 7 days  
x 3ODWHOHWVÂ•[9/L and no transfusion for 7 days 
12. PT/INR <1.[ADDRESS_217150] and PTT (aPTT) <1.[ADDRESS_217151] (unless abnormalities are unrelated to 
coagulopathy or bleeding disorder). When treated with warfarin or other vitamin K 
antagonist, then INR Â” ( Section 6.2.3). 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 33 Ethical/Other 
13. Male and female subjects of re productive potential who agree to use both a highly effective 
methods of birth control (eg, implants, inject ables, combined oral contraceptives, some 
intrauterine devices [IUDs], complete abstinence2, or sterilized partner) and a barrier method 
(eg, condoms, cervical ring, sponge, etc.) duri ng the period of therapy and for [ADDRESS_217152] meet NONE of the following exclusion 
criteria: Disease-Related 
1. Received any previous systemic treatment for cGVHD with the following exception:  
x Corticosteroids for cGVHD received within the 72 hours prior to signing the informed 
consent form.  
2. ,QDELOLW\WREHJLQDSUHGQLVRQHGRVHÂ•  mg/kg/d for the treatment of cGVHD.  
3. Presence of single-organ, genito-urinary involvement with cGVHD as the only manifestation of cGVHD. 
Concurrent Conditions 
4. Received any investigational agent Â”GD\VEHIRUH  randomization. 
5. Received donor lymphocyte infusion (DLI) Â”GD\VEHIRUHUDQGRPL]DWLRQ  
6. Currently active, clinically significant cardiovascular disease, such as uncontrolled 
arrhythmia or Class 3 or 4 congestive heart failure as de fined by [CONTACT_183959]; or a history of myocardi al infarction, unstable angina, 
or acute coronary syndrome within 6 months prior to randomization. 
7. Any uncontrolled active systemic infection or active infection requiring systemic treatment that was ongoing Â”GD\VEHIRUH randomization. This does not include secondary prophylaxis 
of well controlled fungal infections, ongoing treatment of controlle d viral reactivations 
(eg, CMV), or treatment or prophylaxis of controlled low-grade central line infections 
(eg, Staphylococcus epi[INVESTIGATOR_77353]).  
8. Progressive underlying malignant disease or active post-transplant lymphoproliferative 
disease. 
9. History of other malignancy (not including the underlying malignancy that was the indication for transplant), with the following exceptions: 
                                                           
 
[ADDRESS_217153]. http://www.hma.eu/fileadmin/dateien/Human_Medicines/01 
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217154]. 
11. Known bleeding disorders (eg, von W illebrandâ€™s disease or hemophilia). 
12. History of stroke or intracranial hemorrhag e within 6 months prior to randomization. 
13. Known history of human immunodeficiency virus (HIV). 
14. Subjects with chronic liver disease with hepatic impairment per Child-Pugh classification 
Class C ( Appendix E ). Please note that acute liver dysfunction due to cGVHD is not 
applicable to the evaluation of Child-Pugh classification. 
15. Active hepatitis C virus (HCV) or hepatitis B virus (HBV). Subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen or hepatitis C antibody must have a negative polymerase chain reaction (PCR) result before randomization. Those who are PCR positive will be excluded. 
16. Vaccinated with live, attenuated vaccines within 4 weeks of randomization. 
17. Major surgery within 4 weeks of randomization. 
18. Any life-threatening illness, medical condition, or organ system dysfunction that, in the 
investigatorâ€™s opi[INVESTIGATOR_1649], could compromise the subj ectâ€™s safety or put the study outcomes at 
undue risk. 
19. Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of  the stomach or small bowel, symptomatic 
inflammatory bowel disease or ulcerative colitis, or partial or comp lete bowel obstruction. 
20. Subjects requiring treatment with  a strong CYP3A inducer are not eligible, unless a transition 
to an agent with less CY P3A induction is planned ( Appendix D ). 
21. Female subject who is pregnant, breastfeedin g, or planning to become pregnant while 
enrolled in this study or within [ADDRESS_217155] dose of study drug. 
22. Unwilling or unable to participate in all required study evaluations and procedures. 
23. Unable to understand the purpose and risks of th e study and to provide a signed and dated 
informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations). 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217156] in 
Interactive Web Response System (IWRS) to assi gn a screening number. After the subject has 
completed all screening procedur es and has met all requirement s of the inclusion/exclusion 
criteria, the site personnel will update IWRS and answer key questions to randomize the subject, 
and have drug assigned. The first dose of ibrutinib/placebo must be administered after 
randomization, which should be no more than 72 hours (3 days) after the subject has been 
randomized by [CONTACT_10966]. 
Approximately 186 subjects will be  randomized in a 1:1 ratio to each of the 2 treatment arms. 
Treatment Arm A: ibrutinib in combination with prednisone  Treatment Arm B: placebo in combination with prednisone 
The randomization between arms will be stratified according to: 
x Age group (12 to <22 \HDUVROGYVÂ•22 years old) 
x NIH Global Severity grad e (moderate vs. severe) 
x Ongoing use of systemic immunosuppressants that  were initiated for e ither treatment of 
or prophylaxis for acute GVHD (yes vs. no) 
[IP_ADDRESS]. Blinding  
This is a double-blind study; therefore, the subjects, the investigators, and the Sponsorâ€™s study 
team members will be blinded to the treatment assignment. The investigator will not be provided 
with randomization codes. The codes will be maintained within the IWRS, which has the 
functionality to allow the investigator to break the blind for an individual subject if necessary to 
appropriately manage or treat the subject. Data that may potentially unblind the treatment 
assignment (ie, study drug plasma concentrations) will be handled with special care to ensure 
that the integrity of the blind is maintained and the potential for bias is minimized. 
The investigator should contact [CONTACT_183960] e particular situation 
before breaking the blind whenever possible. Tele phone contact [CONTACT_183961] [ADDRESS_217157]'s source 
documents in a secure manner. A subject whos e treatment assignment has been unblinded may 
continue the study treatment if the subject is expe cted to continue receiving clinical benefit. The 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217158] udy visits. The single-blind (ie, subject remains 
blinded to treatment a ssignment) should be maintained provi ded the subjectâ€™s safety is not 
compromised. 
At the time of the futility analyses, the randomization codes and, if require d, the translation of 
randomization codes into treatment and control gr oups will be disclosed to those authorized and 
only for those subjects included in the interim analyses. 
5.2. Study Treatment 
Ibrutinib  (420 mg) or placebo will be given oral ly once daily continuously starting on 
Week [ADDRESS_217159] begins 
another systemic treatment for c GVHD or unacceptable toxicity.  
Prednisone  1 mg/kg/d will be given orally once daily continuously starting on Week [ADDRESS_217160] is succ essfully tapered from the prednisone (see 
Section [IP_ADDRESS].1). Starting prednisone dose may be as low as 0.5 mg/kg/d if a subject cannot 
tolerate higher doses.  
During Screening, prednisone to treat cGVHD ma y be started prior to randomization if the 
clinical condition of the subject necessitates it. If  a subject is started on high dose prednisone for 
treatment of cGVHD prior to randomization, the pa tient must be randomized within 7 days of 
starting high dose prednisone. 5.3. Study Medication 
5.3.1. Ibrutinib/Placebo 
[IP_ADDRESS]. Formulation/Packaging/Storage 
Ibrutinib capsules are provided as a hard gelatin capsule containing [ADDRESS_217161] dose reductions that requi re a dose of 70 mg and will not be used to 
constitute a dose larger than 70 mg (eg, 2 x 70 mg capsules to give 140 mg). 
The ibrutinib (or placebo) capsules will be packaged in opaque high-density polyethylene plastic 
bottles with labels bearing the appropriate label text as required by [CONTACT_40714]. All study drug will be dispensed in child-resistant packaging.  
Refer to the Pharmacy Manual/site investigational product manual for additional guidance on 
study drug storage, preparation and handling. Study drug labels will contain information to meet the applicable regulatory requirements. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 37 [IP_ADDRESS]. Dose and Administration 
Ibrutinib or placebo is administered orally once daily. It is expected that many subjects 
commencing therapy with high dose prednisone will require anti-fungal prophylaxis.  Please see 
Section 6.2.1 for dose modification guidelines with concomitant use of CYP3A inhibitors or 
inducers.  
The capsules are to be taken around the same time each day with 8 ounces (approximately 
240 mL) of water. The capsules should be swallowe d intact and subjects should not attempt to 
open capsules or dissolve them in water. If a dose is not taken at the scheduled time, it can be 
taken as soon as possible on the same day with a return to the normal schedule the following day. 
The subject should not take extra cap sules to make up the missed dose. 
The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typi[INVESTIGATOR_183906]. Ibrutinib will be dispense d to subjects in bottles at each visit. Unused 
ibrutinib dispensed during previous visits must be returned to the site and drug accountability records ( Section 12.8 ) updated at each visit. Returned capsules must not be redispensed to 
anyone. 
[IP_ADDRESS]. Overdose 
Any dose of study drug administered in excess of [ADDRESS_217162] be reported as a SAE in the 
appropriate time frame and documented as clinical sequelae to an overdose.  
There is no specific experience in the management of ibrutinib overdose in patients. No 
maximum tolerated dose (MTD) was reached in th e Phase 1 study in which subjects received up 
to 12.5 mg/kg/day (1400 mg/day). Healthy subjects were exposed up to single dose of [ADDRESS_217163] experienced reversible Grade 4 hepatic enzyme increases (AST and ALT) 
after a dose of 1680 mg. Subjects who ingested more than the recommended dosage should be 
closely monitored and given a ppropriate supporti ve treatment. 
Refer to Section 11.4  for further information regarding AE reporting.  
[IP_ADDRESS]. Dose Modification for Adverse Reactions  
The dose of ibrutinib/placebo must be modified according to the dose modification guidance in Table 1  and Table 2  if any of the following toxicities occur: 
x Grade 4 neutropenia (ANC <500/ Î¼L) for more than 7 days. See Section 6.1  for 
instructions regarding the use of growth factor support 
x Grade 3 thrombocytopenia (platelets <50,000/Î¼ L) in the presence of clinically significant 
bleeding events 
x Grade 4 thrombocytopenia (platelets <25,000/Î¼ L) 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 38 x Grade 3 or 4 nausea, vomiting, or diarrhea if persistent, despi[INVESTIGATOR_9025]-emetic 
and/or anti-diarrheal therapy 
x Any other Grade 4 or unmanageable Grade 3 toxicity  
Adverse events that are considered related to concomitant high dose corticosteroids (eg, hyperglycemia, insomnia) do not require  dose modification or holding of ibrutinib. 
For Grade 3 or 4 atrial fibrillation or persistent atrial fibrillation of any grade, consider the risks and benefits of ib rutinib treatment. If clinically indicated, the use of anticoagulants or 
antiplatelet agents may be considered for the thromboprophylaxis of atrial fibrillation 
(Section 6.2.3).   
For other AEs not listed above, including Grade 2 AEs that are deemed per the investigator 
potentially manageable by [CONTACT_29874], these can be managed with a one dose level reduction. 
In the event that the investigator feels deviation from the recommendations above is required, 
please consult the medical mon itor to discuss for approval. 
If the dose of ibrutinib/placebo is reduced for an adverse event, at the investigatorâ€™s discretion, 
the dose of ibrutinib may be re-escalated after [ADDRESS_217164] be recorded in the Dose 
Administration eCRF.  
Table 1. Ibrutinib/Placebo Dose Modifications 
Occurrence Action to be Taken  
First :LWKKROGVWXG\GUXJXQWLOUHFRYHU\WR*UDGHÂ”RU baseline; may restart at original dose 
level 
Second :LWKKROGVWXG\GUXJXQWLOUHFRYHU\WR*UDGHÂ”RUEDVHOLQHPD\ UHVWDUWDWGRVHOHYHO
lower (eg,  280 mg/day for 420 mg/day dose) 
Third Withhold study GUXJXQWLOUHFRYHU\WR*UDGHÂ”RUEDVHOLQHPD\UHVWDUWDWG RVHOHYHO
lower (eg, 140 mg/day for 420 mg/day dose) 
Fourth Discontinue study drug 
Table 2. Ibrutinib/Placebo Dose Reduction Levels 
Starting Dose Level 420 mg 280 mg 140 mg 
Dose Reduction Level 1 280 mg 140 mg 70 mg 
Dose Reduction Level 2 140 mg 70 mg Discontinue 
Dose Reduction Level 3 Discontinue  Discontinue -- 
For required dose modification fo r hepatic impairment refer to Section [IP_ADDRESS] and for 
concomitant treatment with CYP3A inhibitors refer to Section 6.2.1 .  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 39 [IP_ADDRESS]. Dose Modification for Subjects with Hepatic Impairment 
Dose modifications for hepatic impairment will depend on baseline total bilirubin level and 
subsequent changes in bilirubin levels per Table 3  below. If the elevation of bilirubin is due to a 
non-hepatic cause or Gilbertâ€™ s Syndrome, then no dose modifications are necessary. 
Table 3. Ibrutinib/Placebo Dose Modifications for Subjects with Hepatic Impairment 
Starting Dose Level by 
[CONTACT_183962] Â”[8/1DWEDVHOLQH : 
 420 mg  Bili >1.5-[ADDRESS_217165] at baseline: 
140 mg 
 
On-VWXG\ELOLUXELQOHYHOÂ”[
ULN Continue 420 mg Increase to 420 mg 
On-study bilirubin level >1.5-[ADDRESS_217166] Reduce to 140 mg Continue 140 mg 
On-study bilirubin level >[ADDRESS_217167] x Hold* until bili level >1.5-[ADDRESS_217168] restart at 140mg 
x When bili level Â”[8/1
restart at 420mg x Hold* until bili level >1.5-[ADDRESS_217169] restart at 140mg 
x When bili level Â”[8/1
restart at 420mg 
Bili = bilirubin 
* In cases where the investigator wishes to restart ibrutinib/placebo after ibrutinib/placebo has been 
held for more than [ADDRESS_217170] the medical monitor for approval. 
In the event a patient has had a dose reduction due  to a non-hepatic toxici ty and then develops 
elevated bilirubin level (or vice versa) that re quires a dose reduction, the lower of the two dose 
reductions should be used. The medical monitor should be consulted for any questions involving 
dose reductions. 
[IP_ADDRESS]. Ibrutinib/Placebo Hold after Wit hdrawal of All Immunosuppressants 
At the physicianâ€™s discretion, ibrutinib/placebo ma y be held if ALL of the following conditions 
are met: 
x All systemic immunosuppressants used for the treatment of cGVHD have been 
discontinued. (The continued use of very lo w doses of corticosteroids used only for 
physiologic adrenal replacement is allowed) 
x cGVHD response has been maintained for 12 we eks after complete withdrawal of all 
immunosuppressants (not including ibrutinib/placebo) 
x The subject has received a minimum of 48 weeks of ibrutinib/placebo 
If cGVHD returns/worsens after ibrutinib/placebo has been held for the above criteria, 
ibrutinib/placebo may be re-started after consulting with the medical monitor. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 40 5.3.2. Prednisone  
[IP_ADDRESS]. Formulation/Packaging/Storage 
Prednisone tablets for oral administration are available in multiple strengths. Commercially 
available prednisone will be s upplied by [CONTACT_183963]. The commercial material 
will be relabeled for clinical trial use.  
For situations where a subject who must receive an  IV or alternate formulation of corticosteroid 
(eg, hospi[INVESTIGATOR_183907]), the dose should be eq uivalent to the subjectâ€™s prednisone dose using 
the prednisone equivalency table ( Appendix K ) unless the subjects clin ical condition warrants a 
different dose (eg, stress doses of steroids for sepsis). All doses of corticosteroids must be 
entered into the eCRF. 
Refer to the Pharmacy Manual for additional guidance on prednisone storage, preparation and 
handling. 
[IP_ADDRESS]. Dose and Administration 
Prednisone will be given orally at 1.0 mg/kg/d with rounding to multiples of 5 mg (eg, 15, 20, 
25, etc.). If a prednisone dose of 1.0 mg/kg/d is contra indicated (eg, poorly controlled diabetes, major 
mood disturbances) then the starting dose of prednisone may be reduced to 0.5-1.0 mg/kg/d. 
Subjects unable to receive a starting  dose of prednisone of at least 0.5 mg/kg/d are ineligible for 
the study. 
If, during Screening, the clinical condition of the subject requires immediate initiation of 
treatment with prednisone, pre dnisone may be started prior to randomization. If the subject 
begins prednisone during Screen ing and prior to randomization the eligible subject must be 
randomized within [ADDRESS_217171] be randomized within 
7 days of signing consent.   
[IP_ADDRESS].1. Prednisone Taper 
Prednisone taper shoul d be attempted by [CONTACT_183964] 4 : 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 41 Table 4. Prednisone Taper Schedule 
Study Week # Dose (mg/kg, body weight) 
0 1.0 qd 
2 0.75 qd 
4 0.65 qd 
6 0.50 qd 
8 0.70 qod* 
10 0.55 qod 
12 0.45 qod 
14 0.35 qod 
16 0.25 qod 
18 0.20 qod 
20 0.15 qod 
22 0.10 qod 
24 0.0 
*qod=every other day. #Timing of steroid taper is defined by [CONTACT_183965]. 
The prednisone taper should commence by [CONTACT_5875]  2, but it is understood that considerable 
variation in prednisone tape r will occur depending on the subjectsâ€™ response and other 
intercurrent illnesses. More rapid tapering of prednisone doses is allowed if clinically 
appropriate. Rounding of corticosteroid doses is acceptable.  Decisions about the use of qod or 
alternative dosing schedules (eg, Mon/Wed/Fri) may follow institutional practice. Prednisone 
taper should be completed prior to tapering of other immunosuppr essants unless the clinical 
condition of the subject dictates tapering/discontinuing other me dications sooner (eg, toxicity 
associated with the use of the medication).  
[IP_ADDRESS].2. Flares in cGVHD 
Exacerbation of cGVHD symptoms may occur during prednisone taper or with intercurrent 
illnesses. Temporary re-escalation of prednisone dose is allowe d at the physicianâ€™s discretion. 
Tapering of increased prednisone dose for a flare should begin within 4 weeks. 
[IP_ADDRESS]. Overdose 
The effects of accidental ingestion of large quantit ies of prednisone over a very short period of 
time have not been reported, but prolonged use of  the drug can produce mental symptoms, moon 
face, abnormal fat deposits, fluid retention, excessive a ppetite, weight gain, hypertrichosis, acne, 
striae, ecchymosis, increased sweating, pi[INVESTIGATOR_116760], dry scaly skin, thinning scalp hair, 
increased blood pressure, tachycardia, thrombophlebitis, decreased resistance to infection, 
negative nitrogen balance with delayed bone a nd wound healing, headache, weakness, menstrual 
disorders, accentuated menopausal symptoms, neuropathy, fractures, osteoporosis, peptic ulcer, 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217172] been observed in children.  
Treatment of acute overdosage is  by [CONTACT_183966]. For chronic overdosag e in the face of severe disease requiring 
continuous steroid therapy the dosage of predni sone may be reduced only temporarily, or 
alternate day treatment may be introduced. [IP_ADDRESS]. Dose Modification for Adverse Reactions 
Prednisone will be ta pered by [CONTACT_183967] ( Table 4 ). 
Prednisone suppresses the hypotha lamic-pi[INVESTIGATOR_2117]-adrenal (HPA) axis  and, therefore, doses must 
be tapered slowly after long-term use. The o ccurrence of unmanageable adverse reactions from 
prednisone (eg, poorly controlled hypertension) may require a more rapid reduction in 
prednisone dosing, but may not necessitate a chan ge in dose of study drug (ibrutinib/placebo). 
Dose modifications will be at the discretion of  the physician and should reflect a balance of 
appropriately treating cGVHD a nd minimizing adverse effects. 
5.4. Criteria for Permanent Discontinuation of Ibrutinib/Placebo 
Investigators are encouraged to keep a subject who is experiencing clinical benefit in the study unless significant toxicity puts the subject at risk or routine noncompliance puts the study 
outcomes at risk. For a complete list of criteria for permanent discontinuation of 
ibrutinib/placebo, refer to Section 9.2 . 
An End-of-Treatment visit ( Section 8.2.3) is required for all subject s except for those subjects 
who have withdrawn full consent. 
6. CONCOMITANT MEDICATIONS/PROCEDURES 
Concomitant therapi[INVESTIGATOR_183908] [ADDRESS_217173] dose of study treatment (i brutinib/placebo or corticosteroids), start of 
another therapy for cGVHD, or start of a ne w therapy for progression for the underlying 
malignancy. 
6.1. Permitted Concomitant Medications 
6.1.1. Ancillary Therapy and Supportive Care 
Ancillary therapy and supportive care for cGVHD is  permitted as outlined in the NIH Consensus 
Development Project 2014 Ancillary Therap y and Supportive Care Working Group Report 
(Carpenter 2015 , Appendix L ). In particular, the use of regimen to specifically treat or prevent 
bronchiolitis obliterans are allowed (eg, inhaled steroids/azithromycin/montelukast) and will not 
be considered systemic treatment for cGVHD. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217174] clinical practice (such as for emesis, 
diarrhea, etc.) are permitted. Use of neutrophil gr owth factors (filgrastim and pegfilgrastim) or 
red blood cell growth factors (ery thropoietin) is permitted per ins titutional policy. Transfusions 
may be given in accordance with institutional policy. Anti-fungal prophylaxis should be given as 
outlined in Appendix L . 
After consultation with the medical monitor the following may be considered; localized hormonal or bone sparing treatment  for malignancies, and localized radiotherapy for medical 
conditions other than the underlying disease. 
6.1.2. Systemic Immunosuppressant Therapy 
During the Screening period, the physician will have the discretion to st art prednisone while 
eligibility for the study is being confirmed, howev er, the subject must be randomized within 7 
days of initiating treatment with prednisone. 
Addition of any other new systemic immunosuppressant therapy (including ECP) to treat 
cGVHD is prohibited during Screening and subseque nt enrollment into the study. Addition of a 
new systemic immunosuppre ssant for cGVHD will be consid ered a treatment failure and 
ibrutinib/placebo will be discontinued. 
At enrollment, subjects may be receiving othe r immunosuppressants for the prophylaxis or 
treatment of acute GVHD. Tapering of these other immunosuppressants upon start of 
ibrutinib/placebo or prednisone is permitted (see Section [IP_ADDRESS].1). 
Use of immunosuppressants for reasons other than  treatment for cGVHD should be discussed 
with the medical monitor. 
6.2. Medications to be Used with Caution 
6.2.1. CYP3A Enzyme Inhibitors/Inducers 
Ibrutinib is metabolized primarily by [CONTACT_097]3A4. The dose of ibrutinib/placebo should be adjusted 
for concomitant use of CYP3A inhibitors per Table  5 below: 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 44 Table 5. Ibrutinib/Placebo Dose Modifications for Concomitant Use of CYP3A 
Inhibitors 
CYP inhibitor class Dose modification instructions 
x Mild CYP3A inhibitors 420 mg once daily. No dose adjustment required. 
x Moderate CYP3A inhibitors 420 mg once daily. No dose adjustment required. 
x Voriconazole at any dose  
or 
x Posaconazole  at doses less than or 
equal to suspension 200 mg BID or 
delayed-release tablet 300 mg QD   280 mg once daily 
x Strong CYP3A inhibitors 
or 
x Posaconazole  at higher doses 140 mg once daily or consider alternative with less 
CYP3A inhibitory potential 
Avoid concomitant use of strong CYP3A inducers ( Appendix D ). Consider alternative agents 
with less CYP3A induction and transition to a new agent within [ADDRESS_217175] of common CYP3A inhibitors and inducers is provided in Appendix D . For further 
information, please refer to the cu rrent version of the ibrutinib IB and examples of inhibitors, 
inducers, and substrates can be found at http ://medicine.iupui.edu/clinpha rm/ddis/main-table/. 
This website is continually revised and should be checked frequently for updates. 
6.2.2. Drugs That May Have Their Plasma Concentrations Altered by [CONTACT_147462] a substrate of P-glycoprotein (P-gp), but is a mild 
inhibitor. Ibrutinib is not expected to have systemic drug-drug interactions with P-gp substrates. 
However, it cannot be excluded that ibrutinib coul d inhibit intestinal P-gp after a therapeutic 
dose. There is no clinical data available. Theref ore, to avoid a potential interaction in the GI 
tract, narrow therapeutic range P-gp substrates such as digoxin, should be taken at least 6 hours 
before or after ibrutinib/placebo.  
6.2.3. Antiplatelet Agents  and Anticoagulants 
Supplements such as fish oil and vitamin  E preparations should be avoided. Use 
ibrutinib/placebo with caution in subjects requiring anticoagulants or medications that inhibit 
platelet function. Subjects with congenital bleeding diathesis have not been studied. For guidance 
on ibrutinib/placebo and the use of anticoagulants during procedures/surgeries see Section 6.4 .  
Subjects requiring the use of therapeutic anticoagulation therapy (eg, atrial fibrillation), consider the risks and benefits of continuing ibrutinib treatment. Subjects treated with warfarin (or other 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 45 vitamin K antagonists) should maintain an INR Â” 3.0 and if unable to maintain this level another 
anticoagulant agent should be considered. If ther apeutic anticoagulation is clinically indicated, 
treatment with ibrutinib/placebo should be held while anticoagula tion is being initiated and not 
be restarted until the subject is clinically stable  and has no signs of bleeding. Subjects should be 
observed closely for signs and symptoms of bleeding. No dose reduction is required when study 
drug is restarted.  
6.3. Other Systemic Immunosuppressant Therapy for cGVHD 
Addition of any other new systemic immunosuppressant ther apy (including ECP) to treat 
cGVHD is prohibited during Screening and subseque nt enrollment into the study. The addition 
of other systemic immunosuppressa nt therapy to treat cGHVD will not allow for the appropriate 
assessment of response attributable to ibrutin ib/placebo. The Sponsor must be notified in 
advance (or as soon as possible thereafter) of an y instances in which prohibited therapi[INVESTIGATOR_183909]. 6.4. Guidelines for Ibrutinib Management with Surgeries or Procedures  
Ibrutinib may increase risk of bleeding with i nvasive procedures or surgery. The following 
guidance should be applied to the use of ibrutinib/placebo in the perioperative period for subjects 
who require surgical intervention or an invasive procedure while receiving ibrutinib/placebo.  
6.4.1. Minor Surgical Procedures 
For minor procedures (such as a central line plac ement, skin or needle biopsy, lumbar puncture 
[other than shunt reservoir access], thoracentesi s, or paracentesis) ib rutinib/placebo should be 
held for at least [ADDRESS_217176] is on 
ibrutinib/placebo, it is not necessary to hold ibrutinib/placebo.  
6.4.2. Major Surgical Procedures 
For any surgery or invasive procedure requiring sutures or staples for closure, ibrutinib/placebo 
should be held at least 7 days prior to the in tervention (except for emergency procedures) and 
should be held at least 7 days after the procedure and restarted at the discretion of the investigator when the surgical site is reasonabl y healed without serosanguineous drainage or the 
need for drainage tubes.  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 46 7. STUDY EVALUATIONS 
7.1. Description of Procedures 
7.1.1. Assessments  
[IP_ADDRESS]. Informed Consent Form (ICF) 
Adult subjects must read, understand, and sign th e Institutional Review Board/Research Ethics 
Board/Independent Ethics Committee (IRB/REB/IEC) approved ICF confirming his or her 
willingness to participate in this study before any study-specific screening procedures are 
performed. Consent of minors consists of signed parental permission form and minorâ€™s assent. 
Subjects must also grant permissi on to use protected health information per the Health Insurance 
Portability and Accountability Act (HIPAA). In addition, subjects must sign all approved ICF amendments per the site IRB/REB/IEC guidelines during the course of the study.  
[IP_ADDRESS]. Confirm Eligibility 
All necessary procedures and eval uations must be performed to do cument that the subject meets 
all of the inclusion criteria and none of the exclusion criteria prior to first dose on Day 1 
(Section 4 ). Details of establishing diagnosis of moderate or severe cGVHD are listed in 
Appendix M , Appendix N , and Appendix O . Please refer to NIH Staging and Response 
Assessment Manual for further details. 
All subjects with prior malignancy as the indication for transplantation must be assessed prior to 
randomization to rule out progr ession of underlying malignancy. Assessments are to be 
performed and collected as deemed appropriate  for the follow-up and management for routine 
standard of care of the underlying malignancy. Th e results of these assessments do not have to be 
known prior to randomization. 
An enrollment eligibility form must be completed prior to enrollment into the trial. 
[IP_ADDRESS]. Medical History and Demographics 
The subjectâ€™s relevant medical history through review of medical records and by [CONTACT_183968]. Conc urrent medical signs and symptoms must be documented to 
establish baseline severities. A disease history, including the date of initial diagnosis will be recorded. For subjects <22 years of age at the time of enrollment, medical history will include 
surveillance for potential late effects ( Appendix P ). 
[IP_ADDRESS]. Prior and Concomitant Medications 
All medications from [ADDRESS_217177] dose of 
ibrutinib/placebo or prednisone, start of another therapy for cGVHD, or start of a new therapy 
for progression of underlying ma lignancy will be documented.  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 47 [IP_ADDRESS]. Adverse Events 
The accepted regulatory definition for an AE is provided in Section 11.[ADDRESS_217178] dose of ibrutinib/placebo or prednisone 
until [ADDRESS_217179] dose of ibrutinib/placebo or prednisone, start of new medication for 
cGVHD or start of a new therapy for progression of  the underlying malignancy that meet the AE 
definition must be recorded as AEs in the eCRF . If the subject rolls over into a follow-up study, 
AE collection will stop after the last dose is given as part of that study. Laboratory abnormalities 
designated clinically significant by [CONTACT_183969]. Assessment 
for corticosteroid-related AEs, in particular ( Appendix Q ), should be performed. Additional 
important requirements for AE and SAE reporting are explained in Section 11.4 .  
[IP_ADDRESS]. Physical Examination 
The physical examination will include height (at Screening for adults, and at Screening and 
annually for subjects <22 years at the time of enro llment), weight, and examination per clinical 
practice.  
[IP_ADDRESS]. Karnofsky/Lansky Performance Scale 
The Karnofsky/Lansky Performance Scale is provided in Appendix C . The Lansky scale is to be 
used for all subjects less than 16 years of age. [IP_ADDRESS]. Vital Signs 
Vital signs will include blood pre ssure, heart rate, respi[INVESTIGATOR_697], and body temperature.  
7.1.2. Laboratory 
[IP_ADDRESS]. Hematology 
Hematology will be evaluated by a central laboratory and parameters will include a complete 
blood count: white blood cells, red blood cells, hemo globin, hematocrit, platelets, neutrophils, 
lymphocytes, monocytes, eosinophils, basophils. 
[IP_ADDRESS]. Chemistry (Serum) 
Serum chemistry will be evaluated by a central laboratory and parameters will include sodium, 
potassium, chloride, blood urea nitr ogen (BUN)/Urea, creatinine, glucose, calcium, total protein, 
albumin, AST, ALT, alkaline phosphatase, tota l bilirubin, lactate dehydrogenase (LDH), 
phosphate, uric acid, magnes ium and bicarbonate.  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 48 [IP_ADDRESS]. Infection Surveillance 
Subjects should be monitored clos ely for signs or symptoms of aspergillus infection and other 
opportunistic infections. Screening for infectious agents, including fungal (eg, aspergillus) and 
viral (eg, CMV) infections as appropriate for th e subjectsâ€™ clinical cour se and medical history, 
should be performed.   
[IP_ADDRESS]. Coagulation Studies 
Measurement of PT/INR and aPTT will be performed at Screening using a local laboratory. 
[IP_ADDRESS]. Hepatitis Serologies 
Hepatitis serologies will be evaluated by a local laboratory and include hepatitis C antibody, 
hepatitis B surface antigen, and hepatitis B core antibody. If hepatitis B core antibody, 
hepatitis B surface antigen, or hepatitis C antibody is positive, then PCR to quantitate hepatitis B 
DNA or hepatitis C RNA must be performed a nd must be negative pr ior to randomization. 
Hepatitis serologies and/or PCR obtained as part of standard of care within 28 days prior to randomization are acceptable for use in establishing eligibility. 
[IP_ADDRESS]. Serum Immunoglobulins 
Serum immunoglobulins will be evaluated by a cent ral laboratory and include IgA, IgG and IgM 
levels. [IP_ADDRESS]. Pregnancy Test 
Serum pregnancy test will be required at Screening by [CONTACT_183970]. A urine pregnancy test will also be performed on Day [ADDRESS_217180] may be performed 
more frequently if required by [CONTACT_31665]. 
7.1.3. Diagnostics/Procedures 
[IP_ADDRESS]. Electrocardiograms (ECG) 
Electrocardiograms should be performed at the inve stigatorâ€™s discretion, par ticularly in subjects 
with arrhythmic symptoms (eg, palpi[INVESTIGATOR_814], lightheadedness) or new onset dyspnea.  During visits in which both ECGs and blood draws are performed, ECGs  should be performed 
first. At Screening, a 12-lead ECG is required. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 49 Abnormalities noted at Screening s hould be included in the medical  history. Subjects <[ADDRESS_217181] a second ECG on Week 2 Day 1 during PK testing. This ECG 
should be done 2-4 hours after ibru tinib/placebo has been taken. 
[IP_ADDRESS]. Forced Expi[INVESTIGATOR_1814] 1 Second (FEV1) 
Forced expi[INVESTIGATOR_3741] 1 second (FEV1) sh ould be measured using spi[INVESTIGATOR_96677]1 
measurement should be obtained prior to randomization.  FEV1 values obtained as standard of 
care within 56 days prior to randomization can be used to fulfill the requirement for a baseline 
FEV1 measurement. If FEV1 results are a bnormal at baseline, then subsequent FEV1 
measurements should be obtained ev ery 12 weeks. If the FEV1 result is normal at baseline, then 
subsequent FEV1 measurements should be obt ained every 24 weeks. The NIH Lung score 
should be ascertained with every cGVHD activity assessment regardless of whether a FEV1 is 
performed. 
7.1.4. Pharmacokinetics/Biomarkers  
[IP_ADDRESS]. Pharmacokinetics 
Plasma concentrations of ibrutinib and me tabolite PCI-[ZIP_CODE] after repeated dosing will be 
determined using a validated analytical method. Other potential metabolites of ibrutinib may be 
explored. Refer to Appendix B for PK sample collection schedule. 
If ibrutinib/placebo is on hold or missed at the Week 2 or Week 25 PK evaluation, PK testing 
should be obtained on the next scheduled visit after ibrutinib dose has been stable for a minimum 
of 7 days. 
[IP_ADDRESS]. Biomarkers and Pharmacodynamic Studies 
Biological specimens collected at specified timepoints during the study may be used for 
pharmacodynamic and biomarker assessments as indicated as well as sequencing expression 
analysis, immunophenotypi[INVESTIGATOR_183910]. Refer to Appendix B for 
pharmacodynamic, biomarker and T/B/NK sample collection schedule. 
Samples collected in this study may be stored at  a biorepository for up to 10 years (or according 
to local regulations) for additional research as  new assays are developed for ibrutinib and 
cGVHD. Samples will be used to  better understand the effects of ibrutinib, cGVHD, sensitivity 
and/or resistance to the investigational treatment regimen in this study. The research may begin 
at any time during the study or the post-study storage period. Stored samples will be coded 
throughout the sample storage and analysis process and will not be labeled with personal 
identifiers. 
Specific analysis and platforms may include, but are not limited to, soluble protein isolation 
including chemokine and cytokine, protein identification and quantif ication, viable cell 
manipulation, stimulation and co-cu lture, kinase drug occupancy studies, flow cytometric or 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 50 CyTOF based cell identificati on, and phospho-protein analyses. New analysis platforms and 
assays directed at protein specific outputs may be considered as technologies develop and 
improve or as new relevant disease or therapy markers are recognized. 
[IP_ADDRESS]. Biomarker DNA and RNA Sequencing 
T-cell and B-cell genetic functional diversity will be determined using a combination of TCR 
and BCR sequencing platform data alongsid e functional and immunophenotypi[INVESTIGATOR_183911]. The 
goal of these studies will be to establish study drug related changes to the systemic immune environment of the subjects. 
RNA and DNA species analysis and or RNA/DNA sequencing may be performed on cells 
obtained from biomarkers specimens in an effo rt to quantify the expression or mutation of 
specific genes implicated in cGVHD disease pathogenesis and or therapy response. 
7.2. Sample Collection and Handling 
The actual dates and times of sample collection must be recorded in source documents for 
transcription to the eCRF or central laborat ory requisition form. Refer to the Schedule of 
Assessments ( Appendix A  and Appendix B ) for the timing and frequency of all sample 
collections. 
Instructions for the collection, handling, and sh ipment of samples are found in the Central 
Laboratory Manual. 7.3. Efficacy Evaluations  
7.3.1. NIH Consensus Panel Response Criteria 
Response will be defined using the NIH Consensus Panel Chronic GVHD Activity Assessment 
(Appendix H  and Appendix I ).  
Overall Response: 
Skin, mouth, liver, upper and lower GI, esophagus, l ung, eye, and joint/fascia are the organs or 
sites considered in evaluating overall response.  
x Complete Response (CR) is defi ned as resolution of all manife stations in each organ or 
site.  
x Partial Response (PR) is defi ned as improvement in at least 1 organ or site without 
progression in any othe r organ or site.  
x Disease Progression is defined as clinically m eaningful worsening in one or more organs 
regardless of improvement in other organs. No te that mixed response (ie, improvement in 
at least 1 organ accompanied by [CONTACT_183971]) is considered disease 
progression. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 51 x Stable disease (SD): response that does not meet the criteria for CR, PR, or disease 
progression.  
Please refer to NIH Staging and Response Assessment Manual and Appendix I  for further 
details. 
7.3.2. Lee cGVHD Symptom Scale and SF-36 Questionnaire 
All subjects in the study will complete the Lee cGVHD Symptom Scale ( Appendix F ) and SF-36 
questionnaire (Appendix G ) at all cGVHD activity assessment visits. These questionnaires 
should be administered before other study procedures. 
7.3.3. Late effects surveillance for adolescents (<22 years at randomization) 
Late effects surveillance for adolescents will consist of the collection of data on growth and 
development (height, weight, and Tanner Stage) a nd medical records review for late effects of 
transplantation. This assessment will be performed at Screening and annually up to [ADDRESS_217182] 
randomization ( Appendix P ). 
8. STUDY PROCEDURES 
8.1. Screening Phase 
8.1.1. Screening/Consenting Visit 
The following procedures will be performed at the Screening Visit within 28 days prior to randomization unless otherwise noted: 
x Obtain signed, written informed consent and if applicable, child assent, and parental 
permission 
x Medical history including demographic information 
x Record history related to late effect surveillance for subjects <22 years of age at the time 
of enrollment using the Late-Effects surveillance form ( Appendix P ) 
x Collection of transplant hi story, including indication 
x cGVHD Diagnosis and staging (NIH) (Appendix M , Appendix N , and Appendix O ) 
x Assessment for relapse/progressive disease for subjects receiving transplant for malignant 
disorders 
x Infection surveillance 
x Evaluation of Karnofsky/Lansky performance status ( Appendix C ) 
x Physical examination including, height and weight. Document Tanner stage for subjects 
<22 years of age (subjects Â•22 years may use prior height measurement if available in 
source documents) ( Appendix P)  
x Record AEs since signing the ICF 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217183] concomitant medication history including corticosteroids requirement, 
over-the-counter drugs, vitamins and herbs since 30 days prior to signing ICF 
x cGVHD activity assessment (eg, NIH assessments [ Appendix H  and Appendix J ]). For 
subjects who begin prednisone prior to  randomization, cGVHD activity assessment 
should be completed prior to start of prednisone. If prednisone is started at the time that ibrutinib/placebo is started (Day 1) then activity assessment can be completed any time during Screening up until the day of first dose of ibrutinib/placebo (Day 1).  
x Lee cGVHD Symptom Scale ( Appendix F )/SF-36 questionnaire ( Appendix G ). Perform 
at the same time as cGVHD assessment. 
x FEV1 (see Section [IP_ADDRESS]) 
x Obtain vital signs (including blood pressu re, heart rate, respi[INVESTIGATOR_697], and body 
WHPSHUDWXUHDIWHUWKHVXEMHFW KDVUHVWHGLQWKHVLWWLQJSRVLWL RQIRUÂ•PLQXWHV  
x Obtain blood specimens for the following laboratory tests: 
o Hematology 
o Serum chemistry 
o Coagulation studies: PT/INR, aPTT 
o Hepatitis serologies/PCR 
x T/B/NK sampling ( Appendix B ) 
x Biomarker sampling ( Appendix B ) 
x Obtain 12-lead ECG after the subject has been in a supi[INVESTIGATOR_36068] 
[ADDRESS_217184] may be called to discuss 
potential prednisone dosing changes. The phone call will be documented in the source 
documentation and will be entered in the CRF. 
8.2. Treatment Phase 
8.2.1. Treatment Visits 
[IP_ADDRESS]. Week [ADDRESS_217185] dose with study drug. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 53 Predose 
x Physical examination  
x Vital signs  
x Performance status (KPS/Lansky) ( Appendix C ) 
x cGVHD activity assessment per NIH ( Appendix H  and Appendix J ). Only perform if not 
performed previously during Screening (see Section 8.1.1  above). 
x Lee cGVHD Symptom Scale ( Appendix F )/SF-36 Questionnaire (Appendix G ). Only 
perform if not performed previously during Screening (see Section 8.1.1 above). 
x FEV1. Only perform if not performed previously during Screening (see Section [IP_ADDRESS] ) 
x Hematology 
x Serum chemistry 
x Urine pregnancy test for women of childbearing potential 
x Quantitative serum immunoglobulins (IgA, IgM, IgG) 
x Review of baseline AEs and concomitant medications (including corticosteroid 
requirements) 
x Review of inclusion and exclusion criteria to re-confirm subject eligibility prior to first dosing 
x Pharmacodynamic sampling ( Appendix B ) 
x T/B/NK sampling ( Appendix B ) 
x Biomarker sampling ( Appendix B
) 
Postdose 
x Administer ibrutinib/placebo at specified dose level, and then dispense remaining amount 
to subject for at-home dosing  
x Provide drug diary and dosing instructions to subject  
x Review AEs 
[IP_ADDRESS]. Week 2  
Predose 
x Physical examination 
x Hematology 
x Serum chemistry 
x Vital signs 
x Review AEs and concomitant medications (including corticosteroid requirements) 
x Pharmacokinetic sampling ( Appendix B ) 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 54 Postdose 
x Administer ibrutinib/placebo at specified dose level 
x Pharmacokinetic sampling at 1, 2, 4, and 6 hours postdose ( Appendix B ) 
x For subjects <22 years of age at enrollment: Obtain 12-lead ECG approximately 
2-[ADDRESS_217186] ibrutinib/placebo dose, after the subject has been in a supi[INVESTIGATOR_36068] 10 minutes 
[IP_ADDRESS]. Week 5, 9, 13, 17, 21, 25  
Predose 
x Physical examination  
x Vital signs  
x Performance status (KPS/Lansky) ( Appendix C ) 
x Hematology 
x Serum chemistry 
x cGVHD activity assessment per NIH ( Appendix H  and Appendix J ) (Weeks 5, 13 and 25 
only) 
x cGVHD response assessment ( Appendix I ) (Weeks 5, 13 and 25 only) 
x Lee cGVHD Symptom Scale ( Appendix F )/SF-36 Questionnaire ( Appendix G ) 
(Weeks 5, 13 and 25 only) 
x FEV1 (Week 13 if abnormal at Screening, Week 25 for all subjects, see Section [IP_ADDRESS] )  
x Quantitative serum immunoglobulins (IgA, IgG, and IgM) (Weeks 13 and 25 only) 
x Pharmacokinetic sampling ( Appendix B ) (Week 25 only) 
x Pharmacodynamic sampling ( Appendix B ) 
x T/B/NK sampling ( Appendix B )  
x Biomarker sampling  
x Review returned subject dosing diary 
x Drug accountability  
x Review AEs and concomitant medications (including co rticosteroid requirements)  
Postdose 
x Administer ibrutinib/placebo at specified dose level, and then dispense remaining amount 
to subject 
x Pharmacokinetic sampling at 1, 2, 4, and 6 hours postdose (Week 25 only)  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 55 [IP_ADDRESS]. Week 37, 49, and every 12 weeks thereafter (Â± 7 days) 
Predose 
x Physical examination 
x Vital signs  
x Performance status (KPS/Lansky) ( Appendix C ) 
x Hematology 
x Serum chemistry 
x cGVHD activity assessment per NIH ( Appendix H  and Appendix J )  
x cGVHD response assessment ( Appendix I ) 
x Lee cGVHD Symptom Scale ( Appendix F )/SF-36 Questionnaire ( Appendix G ) 
x FEV1 every 12 weeks if prior FEV1 was abnormal, every 24 weeks if prior FEV1 was 
normal (see Section [IP_ADDRESS])  
x Quantitative serum immunoglobulins (IgA, IgG, and IgM) 
x Pharmacodynamic sampling ( Appendix B ) (Weeks 49, 73, and 97 only) 
x T/B/NK sampling ( Appendix B ) (Weeks 37, 49, 73 and 97 only) 
x Biomarker sampling ( Appendix B ) (Weeks 37, 49, 73 and 97 only) 
x Review returned subject dosing diary 
x Drug accountability 
x Review AEs and concomitant medications (including co rticosteroid requirements)  
Postdose 
x Administer ibrutinib/placebo at specified dose level, and then dispense remaining amount 
to subject 
8.2.2. Progressive Disease Visit 
Progressive Disease visit should be performed at any time during the study,  if based on clinical 
and/or laboratory evaluation, the Investigator susp ects progressive disease. If possible, the visit 
should be performed within [ADDRESS_217187]â€™s previous dose.  
x Physical examination 
x Vital signs  
x Performance status (KPS/Lansky) ( Appendix C ) 
x Hematology 
x Serum chemistry 
x cGVHD activity assessment per NIH ( Appendix H  and Appendix J )  
x cGVHD response assessment ( Appendix I ) 
x Lee cGVHD Symptom Scale ( Appendix F )/SF-36 Questionnaire ( Appendix G ) 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 56 x FEV1 (if not obtained within the previous 12 weeks, see Section [IP_ADDRESS]) 
x Quantitative serum immunoglobulins (IgA, IgG, and IgM) 
x Review AEs and concomitant medications (including corticosteroid requirements) 
x Review returned subject dosing diary 
x Final drug accountability 
x Pharmacodynamic sampling ( Appendix B ) 
x T/B/NK sampling ( Appendix B ) 
x Biomarker sampling ( Appendix B ) 
8.2.3. End-of-Treatment Visit 
An End-of-Treatment visit should occur 30 days (Â± 7 days) from the last dose of study drug or 
prior to the start of a new cGVHD treatment. If  the subject starts a new cGVHD treatment less 
than 7 days after the Progressive Disease vis it, only those procedures not conducted at the 
Progressive Disease visit should be performed at the End-of-Treatment visit. If ibrutinib/placebo 
is held after Week 48 due to response (see Section [IP_ADDRESS] ), the End-of-Treatment visit should 
occur 30 days after ibrutinib/placebo was put on hold. 
The following procedures will be performed at the End-of-Treatment visit: 
x Physical examination 
x Vital signs  
x Performance status (KPS/Lansky) ( Appendix C ) 
x Hematology 
x Serum chemistry 
x cGVHD activity assessment per NIH ( Appendix H  and Appendix J ) (if not performed 
within previous 30 days) 
x cGVHD response assessment ( Appendix I ) (if not performed within previous 30 days) 
x Lee cGVHD Symptom Scale ( Appendix F )/SF-36 Questionnaire ( Appendix G ) (if not 
performed within previous 30 days) 
x FEV1 (if not obtained within previous 12 weeks) 
x Quantitative serum immunoglobulins (IgA, IgG, and IgM) 
x Review AEs and concomitant medications (including corticos teroid requirements and any 
new cGVHD treatment if applicable) 
x Review return ed subject dosing diary 
x Final drug accountability 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217188] has completed the End-of-Treatme nt visit they will enter the Follow-up Phase. 
Subjects that withdraw from tr eatment for reasons other than progressive cGVHD or progression 
of their underlying malignancy will par ticipate in ongoing response follow-up.  
8.3.1. Response Follow-up 
Subjects who discontinue ibrutinib/placebo for reasons other than progressive cGVHD or 
progression of underlying malignancy will be followed at pre-specified response assessment time 
points (Weeks 5, 13, 25 and every 12 weeks thereafter) by [CONTACT_183972]. During th is period, the following procedures will be 
performed: 
x Physical examination 
x Vital signs  
x Performance status (KPS/Lansky) ( Appendix C ) 
x Hematology 
x Serum chemistry 
x cGVHD activity assessment per NIH ( Appendix H  and Appendix J )  
x cGVHD response assessment ( Appendix I ) 
x Lee cGVHD Symptom Scale ( Appendix F )/SF-36 Questionnaire ( Appendix G ) 
x FEV1 every [ADDRESS_217189] progression of their underlying malignancy 
(for subjects who have not withdrawn consent), they will be contact[CONTACT_147464] 
12 weeks (Â±14 days) by [CONTACT_183973] a ssess survival and the use of alternative 
cGVHD therapy. In addition, subjects who have progressive cGVHD will continue to have the 
Lee Symptom Scale and SF-[ADDRESS_217190] was randomized. Adolescents (<22 years of age at the time of randomization) will be 
followed for up to 5 years after randomization; however, the study may close after the last 
patient below [ADDRESS_217191] 
completed a minimum of 1 year of follow-up. S ubjects may be rolled over to a long-term 
extension study for long-term follow-up.  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217192] to follow up, or has not withdrawn consent before the end of study.  
9.2. Discontinuation from  Ibrutinib/Placebo 
Ibrutinib/placebo will be discontinued in the event of any of the following events: 
x Subject begins treatment with another syst emic therapy (including ECP) for cGVHD 
x cGVHD progression 
x Progression or relapse of the malignancy that was the indication for transplantation or 
development of PTLD  
x Unacceptable toxicity: an intercurrent illness or AE that prevents further ibrutinib/placebo administration despi[INVESTIGATOR_183912] 
x Noncompliance with study medication 
x Investigatorâ€™s decision (such as chronic noncom pliance, significant protocol deviation, or 
best interest of the subject) 
x Withdrawal of consent for treatment by [CONTACT_1130] 
x Unblinding at primary efficacy analysis 
x Study termination by [CONTACT_2728] 
x Subject becomes pregnant 
x Death 
All subjects, regardless of reason for discon tinuation of ibrutinib/placebo will undergo an 
End-of-Treatment visit and be followed as outlined under Section 8.[ADDRESS_217193] discontinues 
ibrutinib/placebo treatment due to cGVHD progression and should provide documentation of 
cGVHD progression for review by [CONTACT_3433] e Sponsorâ€™s medical monitor.  
9.3. Withdrawal from Study 
Withdrawal from study (including all follow-up ) will occur under the following circumstances: 
x Withdrawal of consent for follow-up observation by [CONTACT_423] 
x Lost to follow-up 
x Study completion / termination 
x Death 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217194] withdraws before completing th e study, the following information should be 
documented in the source documents: 
x Reason for withdrawal; 
x Whether the subject withdraws full consent (i e, withdraws consent to treatment and all 
further contact) or partial consent (ie, wit hdraws consent to treatment but agrees to 
participate in follow-up visits); and/or, withdraws consent from future biomarker 
research. 
10. STATISTICAL METHODS AND ANALYSIS  
Statistical analysis will be done by [CONTACT_183974]. A general 
description of the statistical met hods to be used to analyze the efficacy and safety data is outlined 
below. Specific details will be provided in the Statistical Analysis Plan.  
10.1. Analysis Sets 
10.1.1. Intention-to-Treat Population (ITT) 
The ITT Population is defined as all subject s who are randomized in the study. The ITT 
population will be used for all efficacy analyses. The mITT Population is defined as all subjects who are randomized in the study (ITT) and who 
do not have evidence of progression of underlying  malignancy from measurements made at or 
before the time of randomizati on. If indicated, the mITT population may be used for additional 
efficacy analyses. 10.1.2. Safety Population (SP) 
The Safety Population will consis t of all randomized subjects who received at least one dose of 
any study drug.  10.2. Sample Size Determination 
The null hypothesis is that the two treatment arms  have the same response rate at 48 weeks and 
the alternative hypothesis is that the re sponse rates of two arms are different. 
Assuming a response rate of 30% at 48 weeks for Arm B (placebo + prednisone), a sample size 
of [ADDRESS_217195] 80%  power to detect a 20% difference in the 
response rates at 48 weeks between the 2 treatment arms (Arm A â€“ Arm B) at an alpha level of 
5% (2-sided). 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217196] Information 
The distribution of subjects by [CONTACT_183975]. The number of subjects randomized, dos ed, and discontinued will be summarized. 
Treatment discontinuation will be summarized according to the reasons for discontinuation and 
by [CONTACT_2939]. 
Demographic and baseline variable s and baseline disease characteristics will be summarized by 
[CONTACT_2939]. 10.4. Efficacy Analyses  
10.4.1. Primary Efficacy Endpoint 
The primary efficacy endpoint of this study is the response rate at 48 weeks (ie, the proportion of 
responders [CR or PR]). Respons e will be defined by [CONTACT_183976] (2014). 
A subject will not be considered as a responder at 48 weeks if the response was not CR or PR, or 
if he/she meets any of following criteria:  
x Starts a second-line systemic therapy for cGVHD at or prior to the response assessment at 
[ADDRESS_217197] 
will be used to compare the proporti ons between the two treatment arms. 
10.4.2. Secondary Endpoints for Efficacy 
The secondary efficacy endpoints are: 
x Response rate at 24 weeks (the proportion of re sponders [CR or PR]) as defined by [CONTACT_183958] (2014) 
x Duration of response (DOR) will be defined fr om the time of initial partial or complete 
response until progression of cGVHD 
x Proportion of subjects with ster oid dose reduction to a level of  less than 0.15 mg/kg/d at 
24 weeks 
x Time to withdrawal of all immunosuppressants (with the exception of ibrutinib/placebo)  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 61 x Overall survival (OS) is defined as the time from randomization until death due to any 
cause  
x Improvement in Lee cGVHD Symptom Scale scores will be compared between the two 
treatment arms 
Proportion of subjects with impr ovement in overall score on the Lee cGVHD Symptom Scale 
and the proportion of subjects with steroid dos e reduction will be analyzed using the same 
method for the primary efficacy endpoint. The Kaplan Meier methodology will be used to 
estimate the distribution of OS for each trea tment group. The log-rank test will be used to 
compare the OS between the 2 treatment arms. Time to withdrawal of all immunosuppressants 
will be analyzed using the same method used for OS. 
Duration of response is defined as the interval between the date of initial documentation of a 
response (PR or better), and the date of first documented evidence of progressive cGVHD or 
death for responders only. Responders will include  subjects who achieve response (PR or better) 
based on NIH 2014 cGVHD criteria. Non-responders  will be excluded from the analysis for 
DOR. Median duration of response will be estimated using Kaplan Meier methodology. 
10.4.3. Exploratory Endpoints 
x Pharmacokinetics (PK) parameters of ibrutinib when administered in combination with 
prednisone in subjects with c GVHD including adolescent subjects 
x Pharmacodynamic characteristics (including BTK and ITK occupancy) of ibrutinib in 
subjects with cGVHD 
x Biomarkers relevant to disease biology  and therapy with ibrutinib for cGVHD 
x Summary scales of SF-[ADDRESS_217198] quantifiable concentration will be treated as zero in the 
summary statistics. All subjects and samples excluded from the analysis will be clearly 
documented in the PK report. 
Descriptive statistics will be us ed to summarize ibrutinib and PCI-[ZIP_CODE] concentrations at each 
sampling time point and PK para meters of ibrutinib and PCI-[ZIP_CODE] (including, but not limited 
to: C max, tmax, AUC last, and t 1/2). 
Individual and mean plasma ibrutinib and PCI-[ZIP_CODE] concentration time pr ofiles will be plotted. 
Ibrutinib data from this study may also be combined with data from other studies performed with 
ibrutinib in subjects with hematologic malignanc ies as part of a population-PK analysis using 
nonlinear mixed effects models. For the population-PK  analysis, covariates that could potentially 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 62 correlate with plasma PK parameters will be evaluated. The results of the population-PK 
analyses (if performed) will be presented in a separate report. 
Biomarker and Pharmacodynamics 
The following biomarker assessments will be undertaken:  1. Sequence-directed Immune Function Assessment 
2. Cytokine, Chemokine, and Soluble Biomarker Assessment 
3. Co-culture Immunologic Function Tests 
4. CyTOF-based Phospho-immunophenotypi[INVESTIGATOR_183913]/PD and biomarkers will be evaluated separately and will not be covered in the statistical 
analysis plan (SAP). 
Patient Reported Outcomes 
SF-36 summary scores will be evaluated; detailed analyses will be covered in the statistical 
analysis plan (SAP).   
10.5. Safety Analysis 
Analysis of safety data w ill be conducted on the safety popul ation, which includes randomized 
subjects who receive at least 1 dose of ibrutinib/p lacebo. The baseline value is defined as the last 
value collected on or prior to the first dose date of ibrutinib/placebo, whichever comes first. 
The safety variables to be summarized include  exposure to ibrutinib/placebo and prednisone, 
AEs, clinical laboratory test results (hematolog y and chemistry), Karnofsky/Lansky performance 
status, and vital sign measurements. In general, safe ty data will be tabulated or listed. No formal 
statistical testing is planned.  Growth and development and late effects will be summarized in adolescent subjects. 
Adverse Events 
The verbatim terms used in the eCRF by [CONTACT_183977] (MedDRA).  
Treatment-emergent period is defined as the period of time from the first dose of study treatment, 
until the earlier of:  
x Thirty days following the last dose of ibru tinib/placebo or prednisone whichever occurs 
later 
OR 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 63 x The start date of a new therapy for cGVHD or for the progression of the underlying 
malignancy. 
The TEAEs are those events that: 
x Are not present prior to the treatment-emergent period and occur during the treatment-emergent period, 
x Are considered related to study drug by [CONTACT_941] i nvestigator regardless of the start dates of the 
events, or 
x Are present prior to the treatment-emergent period but worsen in severity during the 
treatment-emergent period or are subsequently considered related to study drug by [CONTACT_093].  
All treatment-emergent AEs will be summarized. For each AE, the numbe r and percentage of 
subjects who experience at least one occurrence of the given event will be summarized. The 
number and percent of subjects with TEAEs will be summarized according to intensity 
(CTCAE, v4.03) and drug relationship, as well as categorized by [CONTACT_39812]. Summaries and listings may be pr ovided, as appropriate, for those subjects who 
die, who discontinue treatment due to an AE, or who experience a severe or a SAE. 
Clinical Laboratory Tests 
Laboratory tests will be summarized separately for hematology and serum chemistry. All laboratory values will be graded using the  NCI CTCAE v4.03. The worst toxicity grade during 
the study will be tabulated. 
Steroid-related Toxicities 
Treatment-emergent steroid-related AEs will be summarized by [CONTACT_183978] ( Appendix 
Q). The number and percent of subjects with steroids related TEAEs will be summarized 
according to intensity ( CTCAE, v4.03) and will be categorized by [CONTACT_39812].  10.6. Interim Futility Review  
An interim analysis (for futility only) will be performed for the first 50 subjects who complete 
the Week 25 visit or discontinue study drug before this time. The independent DMC will review 
the interim futility analysis re sults and make a recommendation accordingly. Details regarding 
the interim futility review will be described in the DMC charter.  
10.7. Data Monitoring Committee (DMC) 
An independent DMC will be established to monitor data on an ongoing basis to ensure the 
continuing safety of the subjects enrolled in th is study and to meet efficacy objectives. The 
committee will meet periodically to review interim data. After the review, the DMC will make 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217199] Operating Procedures in 
conformity with regulatory requi rements worldwide to ensure a ppropriate reporting of safety 
information; all clinical studies  conducted by [CONTACT_183979]. 
11.1. Definitions  
11.1.1. Adverse Events 
An AE is any untoward medical occurrence in a subject administered a pharmaceutical product 
and which does not necessarily have a causal re lationship with this treatment. An AE can 
therefore be any unfavorable and unintended sign  (including a clinical ly significant abnormal 
laboratory finding, for example), symptom, or dise ase temporally associated with the use of an 
investigational study drug, whether or not considered related to the study drug ( ICH-E2A 1995 ). 
For the purposes of this clinical study, AEs include events which are either new or represent 
detectable exacerbations of pre-existing conditions. 
The term â€œdisease progressionâ€ should not be reported as an AE term. As an example, 
"worsening of underlying disease" or the clini cal diagnosis that is associated with disease 
progression should be reported. 
Adverse events may include, but are not limited to: 
x Subjective or objective symptoms provided by [CONTACT_3184]/or observed by [CONTACT_183980]. 
x Any AEs experienced by [CONTACT_183981]. 
x AEs not previously observed in the subject that emerge during the protocol-specified AE 
reporting period, including signs or symptoms a ssociated with the underlying disease that 
were not present before the AE reporting period.  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 65 x Complications that occur as a result of pr otocol-mandated interv entions (eg, invasive 
procedures such as biopsies). 
The following are NOT considered AEs: 
x Pre-existing Condition:  A pre-existing condition (documented on the medical history 
CRF) is not considered an AE unless the seve rity, frequency, or character of the event 
worsens during the study period. 
x Pre-planned or Elective Hospi[INVESTIGATOR_059]:  A hospi[INVESTIGATOR_147440], but rather a therapeutic intervention. However, if during 
the pre-planned hospi[INVESTIGATOR_183914] o ccurs, which prolongs the hospi[INVESTIGATOR_183915], the event will be considered an SAE. Surgeries or 
interventions that were under consideration, but not performed before enrollment in the study, will not be considered serious if they are performed after enrollment in the study for a condition that has not changed from its baseline level. Elective hospi[INVESTIGATOR_183916], solely for the administration of chemotherapy, or due to long travel 
distances are also not SAEs. 
x Diagnostic Testing and Procedures:  Testing and procedures should not be reported as 
AEs or SAEs, but rather the cause for th e test or procedure should be reported. 
11.1.2. Serious Adverse Events 
A SAE based on International Conference on Harmonisation (ICH) and EU Guidelines on 
Pharmacovigilance for Medicinal Products for Hu man Use is any untoward medical occurrence 
that at any dose: 
x Results in death (ie, the AE actually causes or leads to death). 
x Is life-threatening. Life-threatening is defined as an AE in which the subject was at risk of death at the time of the event. It does not refer to an event which hypothetically might have caused death if it were mo re severe. If either the investigator or the Sponsor believes 
that an AE meets the definition of life-threatening, it will be considered life-threatening. 
x Requires in-patient hospi[INVESTIGATOR_12191] >24 hours or prolongation of existing hospi[INVESTIGATOR_059]. 
x Results in persistent or significant disability/incapacity (ie, the AE results in substantial disruption of the subjectâ€™s ability to conduct normal life functions). 
x Is a congenital anomaly/birth defect. 
x Is an important medical event that may not result in death, be immediately life-threatening or require hospi[INVESTIGATOR_059], but may be considered an SAE when, based upon appropriate medical judgment, th e event may jeopardize the subject or 
subject may require intervention to prevent one of the other outcomes listed in this 
definition. Examples of such events are inte nsive treatment in an emergency department 
or at home for allergic bronchospasm, blood dy scrasias, or convulsion that does not result 
in hospi[INVESTIGATOR_059]; or development of  drug dependency or drug abuse. 
Given that the investigatorâ€™s perspective may be informed by [CONTACT_36091], 
and the Sponsor is likely to have broader knowledge of the drug and its effects to inform its 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 66 evaluation of the significance of the event, if eith er the Sponsor or the investigator believes that 
the event is serious, the event will be considered serious. 
11.1.3. Severity Criteria (Grade 1-5) 
Definitions found in the Common Terminology  Criteria for Adverse Events version 4.03 
(CTCAE v4.03 ) will be used for grading the severity (intensity) of AEs. The CTCAE v4.[ADDRESS_217200] experience any AE not liste d in the CTCAE v4.03, the following grading 
system should be used to assess severity: 
x Grade 1 (Mild AE) â€“ experiences which are usually transient, requiring no special 
treatment, and not interfering with the subjectâ€™s daily activities 
x Grade 2 (Moderate AE) â€“ experiences which introduce some level of inconvenience or 
concern to the subject, and which may interfere with daily activities, but are usually 
ameliorated by [CONTACT_14212] 
x Grade 3 (Severe AE) â€“ experiences which are unacceptable or intolerable, significantly interrupt the subjectâ€™s usual daily activity, and require systemic drug therapy or other 
treatment 
x Grade 4 (Life-threatening or disabling AE) â€“ ex periences which cause the subject to be in 
imminent danger of death 
x Grade 5 (Death related to AE) â€“ experi ences which result in subject death 
11.1.4. Causality (Attribution)  
The investigator is to assess the causal relation (ie, whether there is a reasonable possibility that 
the study drug caused the event) using the following definitions: 
Not Related: Another cause of the AE is more plausible; a temporal sequence 
cannot be established with the onset  of the AE and administration of 
the investigational product; or, a causal relationship is considered 
biologically implausible. 
Unlikely: The current knowledge or informati on about the AE indicates that a 
relationship to the investiga tional product is unlikely. 
Possibly Related: There is a clinically plausible time sequence between onset of the AE and administration of the investig ational product, but the AE could 
also be attributed to concurrent or  underlying disease, or the use of 
other drugs or procedures. Possibly  related should be used when the 
investigational product is one of several biologically plausible AE 
causes. 
Related: The AE is clearly related to us e of the investigational product. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 67 11.2. Unexpected Adverse Events 
An â€œunexpectedâ€ AE is an AE that is not listed in the IB/package insert or is not listed at the 
specificity or severity that has been obser ved. For example, hepatic necrosis would be 
â€œunexpectedâ€ (by [CONTACT_14213]) if the IB referred only to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be â€œunexpectedâ€ 
(by [CONTACT_14214]) if the IB/package insert listed only cerebral vascular accidents. 
"Unexpected" also refers to AEs that are mentioned in the IB as occurring with a class of drugs 
or as anticipated from the pharmacological prope rties of the drug, but are not specifically 
mentioned as occurring with the study drug under investigation. 
11.3. Special Reporting Situations 
Special reporting situation on a Sponsor study ma y require expedited re porting and/or safety 
evaluation include, but are not limited to: 
x Overdose of any study drug 
x Suspected abuse/misuse of a study drug 
x Inadvertent or accidental exposure to a study drug 
x Medication error involving a product (with or without subject exposure to the study drug, 
eg, name [CONTACT_2976]) 
Occurrence of any special reporting situations should be recorded in the eCRF. If any special 
reporting situation meets the criteria of an AE, it should be recorded on the AEs eCRF. If the AE 
is considered serious, it should be recorded on the AEs eCRF as serious and should be reported 
on the Serious Adverse Event Report Form. The Serious Adverse Event Report Form should be 
sent via email or fax to Pharma cyclics Drug Safety or designee within [ADDRESS_217201]â€™s medical record and on the AEs 
CRF and, when applicable, on the Serious Adverse Event Report Form. 
Each recorded AE or SAE will be described by [CONTACT_13662] (ie, start and end dates), severity, 
regulatory seriousness criteria (if applicable), suspected relationship to the investigational 
product, and any actions taken. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217202] dose of study drug (ibrutinib/placebo or prednisone) 
or the start date of a new therapy for cGVHD. The occurrence of AE at the time the ICF is 
signed until first dose should be recorded under me dical history in the eCRF form. All medical 
occurrences after the first dose of study drug until [ADDRESS_217203] dose of study 
drug should also be reported if considered rela ted to study drug. Resolution information after 30 
days should be provided.  
Progression of cGVHD should NOT be reported as an event term, but instead symptoms/clinical 
signs of disease progression may be reported (see Section 11.1.1). 
All AEs, regardless of seriousness, severity, or presumed relationship to study drug, must be 
recorded using medical terminology in the source document. All records will need to capture the 
details of the duration and the severity of each epi[INVESTIGATOR_1865], the action taken with respect to the study 
drug, investigatorâ€™s evaluation of its relations hip to the study drug, and the event outcome. 
Whenever possible, diagnoses should be given when signs and symptoms are due to a common 
etiology (eg, cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper respi[INVESTIGATOR_4416]"). Investigators must record in the CRF their opi[INVESTIGATOR_183917]. All measures required for AE management must be 
recorded in the source document and repo rted according to Sponsor instructions. 
All deaths should be reported with the primary cause of death as the AE term, as death is 
typi[INVESTIGATOR_36069], not the even t itself. Autopsy and postmortem reports must be 
forwarded to the Sponsor, or designee, as ou tlined above, if allowed per local regulatory 
guidelines. 
If a death occurs within [ADDRESS_217204] be reported to 
the Sponsor as a SAE.  11.4.3. Expediting Reporting Requirements for Serious Adverse Events 
All SAEs (initial and follow-up information) will be reported on the Serious Adverse Event 
Report Form and sent via email or fax to Phar macyclics Drug Safety, or designee, within 
[ADDRESS_217205] follow-up and 
other additional information from the investigat or (eg, hospi[INVESTIGATOR_063]/discharge notes and 
laboratory results). The contact [CONTACT_3031] (phone, email and fax) for Pharmacyclics Drug Safety can be found on the Serious Advers e Event Report Form and instructions. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217206]'s participation in the study, must be followed until any of the 
following occurs: 
x The event resolves 
x The event stabilizes 
x The event returns to baseline, if a baseline value/status is available 
x The event can be attributed to agents other th an the study drug or to factors unrelated to 
study conduct 
x It becomes unlikely that any additional info rmation can be obtained (subject or health 
care practitioner refusal to provide additiona l information, lost to follow up after 
demonstration of due diligence with follow-up efforts) 
The Sponsor assumes responsibility for appropriate reporting of AEs to the regulatory authorities 
and governing bodies according to the local regulations.  
The investigator (or Sponsor where required) must report these events to the appropriate 
Independent Ethics Committee/Institutional Review Board (IEC/IRB) that approved the protocol 
unless otherwise required and documented by [CONTACT_6179]/IRB. 
11.4.4. Pregnancy 
Before study enrollment, subjects must agree to take appropriate measures to avoid pregnancy. However, should a pregnancy occur in a female  study subject, consent to provide follow-up 
information regarding the outcome of the pregnancy and the health of the infant until [ADDRESS_217207] dose of study drug (s). 
Any female subjects receiving study drug (s) who become pregnant must immediately 
discontinue study drug. The investigator should counsel the subject, discussing any risks of 
continuing the pregnancy and any possible effects on the fetus. 
Although pregnancy itself is not regarded as an  AE, the outcome will need to be documented. 
Any pregnancy occurring in a female subject or  female partner of a male subject must be 
reported from the time of first dose up until [ADDRESS_217208] dose of study drug (s). Any 
occurrence of pregnancy must be recorded on th e Pregnancy Report Form Part I and sent via 
email or fax to Pharmacy clics Drug Safety, or designee, within  24 hours of learning of the event. 
All pregnancies will be followed for outcome, which is defined as elective termination of the 
pregnancy, miscarriage, or delivery of the fetus.  For pregnancies with an outcome of live birth, 
the newborn infant will be followed until 30 days old by [CONTACT_36094]. Any congenital anomaly/birth defect noted in the infant must be reported as a SAE. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217209] (AESI) 
Specific AEs, or groups of AEs, will be followed as  part of standard safety monitoring activities 
by [CONTACT_1034]. These events (regardless of se riousness) should be reported on the Serious 
Adverse Event Report Form and sent  via email or fax to Pharmacyc lics Drug Safety, or designee, 
within 24 hours of awareness.  [IP_ADDRESS]. Major Hemorrhage 
Major hemorrhage is defined as any of the following: 
x Any treatment-emergent hemorrhagic  AEs of Grade 3 or higher*  
x Any treatment-emergent serious adverse events of bleeding of any grade 
x Any treatment-emergent central nervous sy stem hemorrhage/hematoma of any grade 
*All hemorrhagic events requiring transfusion of red blood cells should be reported as Grade [ADDRESS_217210] according to Section 11.4.7  above. 
12. STUDY ADMINISTRATION AND INVESTIGATOR OBLIGATIONS  
12.1. Regulatory and Ethical Compliance 
This clinical study was designed and will be implemented in accordance with the protocol, the ICH Harmonized Tripartite Guidelines for Good Clinical Practices, with applicable local 
regulations (including US Code of Federal Regulations [CFR] Title 21 and European Directive 
2001/20/EC), and with the ethical principles laid down in the Declaration of Helsinki.  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217211] (IRB), Research Ethics Board (REB) and Independent 
Ethics Committee (IEC) Approval 
The investigator will submit this protocol, th e ICF, IB, and any other relevant supporting 
information (eg, all advertising materials or materials given to the subject during the study) to the 
appropriate IRB/REB/IEC for review and approva l before study initiation. Amendments to the 
protocol and ICF must also be  approved by [CONTACT_1201]/REB/IEC before the implementation of 
changes in this study. 
The investigator is responsibl e for providing the IRB/REB/IEC with any required information 
before or during the study, such as SAE ex pedited reports or st udy progress reports. 
The IRB/REB/IEC must comply with current [LOCATION_002] (US) regulations (Â§21 CFR 56) as 
well as country-specific national regulations and/or local laws. 
The following documents must be provided to Ph armacyclics or its authorized representative 
before entering subjects in this study: (1) a copy of the IRB/REB/IEC letter that grants formal 
approval; and (2) a copy of the IRB/REB/IEC-approved ICF.  
12.3. Informed Consent 
The ICF and process must comply with the US re gulations (Â§ 21 CFR Part 50) as well as country 
specific national regulations and/or local laws. Parental permission will be obtained for subjects 
who are below the age of legal consent and asse nt procedures for minors will follow country 
specific national regulations. The ICF will document the study-specific information the investigator or his/her designee provides to the subj ect and the subjectâ€™s agreement to participate.  
The investigator or designee (designee must be listed on the Delegati on of Authority log), must  
explain in terms understandable to the subject the purpose and nature of the study, study 
procedures, anticipated benefits, potential risks, possible AEs, and any discomfort participation in the study may entail. This process must be documented in the subjectâ€™s source record. Each 
subject must provide a signed and dated ICF be fore any study-related (nonstandard of care) 
activities are performed. The original and any amended signed and dated consent forms must 
remain in each subjectâ€™s study file at the stud y site and be available for verification by [CONTACT_33483]. A copy of each signed cons ent form must be given to the subject at the 
time that it is signed by [CONTACT_423]. 
12.4. Quality Control and Quality Assurance 
Sponsor shall implement and maintain quality cont rol and quality assurance procedures to ensure 
that the study is conducted and data are genera ted, documented and reporte d in compliance with 
the protocol, GCP, and applicable regulatory requirements. This study shall be conducted in 
accordance with the provisions of the Declaration of Helsinki (October 2008) and all revisions 
thereof, and in accordance with the Food and Drug Administration (FDA) regulations (21 CFR 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 72 Parts 11, 50, 54, 56, and 312, Subpart D â€“ Responsibilities of Sponsors and investigators) and 
with the ICH guidelines on GCP ( ICH E6 ).  
12.5. Protected Subject Health Information Authorization 
Information on maintaining subject confidentiality in accordance to individual local and national 
subject privacy regulations must be provided to each subject as part of the informed consent 
process (refer to Section [IP_ADDRESS]), either as part of the ICF or as a separate signed document 
(for example, in the US, a site-specific HIPAA consent may be used). The investigator or 
designee must  explain to each subject that for the evaluation of study results, the subjectâ€™s 
protected health information obtained during the st udy may be shared with Pharmacyclics and its 
designees, regulatory agencies, and IRBs/REBs/ IECs. As the study Sponsor, Pharmacyclics will 
not use the subjectâ€™s protected health information or disclose it to a third party without applicable 
subject authorization. It is the investigatorâ€™s  or designeeâ€™s responsibility to obtain written 
permission to use protected health information from each subject. If a subject withdraws permission to use protected health information, it is  the investigatorâ€™s responsibility to obtain the 
withdrawal request in writing from the subject and to ensure that no further data will be 
collected from the subject. Any data collected on the subject before withdrawal will be used in 
the analysis of study results. 
During the review of source documents by [CONTACT_941] m onitors or auditors, the confidentiality of the 
subject will be respected with strict adherence to professional standards and regulations. 12.6. Study Files and Record Retention 
The investigator must  keep a record of all subjects who have consented to enroll in the study. 
For those subjects subsequently excluded from enrollment, the reason(s) for exclusion is to be 
recorded. 
The investigator/study staff must maintain adequa te and accurate records to enable the conduct 
of the study to be fully documented and the stud y data to be subsequent ly verified. Essential 
documentation includes, but is not limited to, the IB, signed protocols and amendments, 
IRB/REB/IEC approval letters (dated), signed  Form FDA 1572 and Financial Disclosures, 
signed ICFs (including subject confidentiality information), drug dispensing and accountability 
records, shippi[INVESTIGATOR_36075]-related materials, signed 
(electronically), dated and completed case re port forms (CRFs), and documentation of CRF 
corrections, SAE forms transmitted to Pharmacyclics and notification of SAEs and related reports, source documentation, nor mal laboratory values, decodi ng procedures for blinded 
studies, curricula vitae for study staff, and all relevant correspondence and other documents 
pertaining to the conduct of the study. 
All essential documentation will be retained by [CONTACT_114824] [ADDRESS_217212] marketing application is approved for the drug for the indication for which it is being 
investigated and until there are no pending or contemplated marketing applications; or, if no 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217213] notify Pharmacyclics and obtain written approval from Pharmacyclics 
before destroying any clinical study documents or images (eg, scan, radiograph, ECG tracing) at 
any time. Should an investigator wish to assign th e study records to another party or move them 
to another location, advance written notice will be  given to Pharmacyclic s. Pharmacyclics will 
inform the investigator of the date that study records may be destroyed or returned to Pharmacyclics. 
Pharmacyclics must be notified in advance of, and Pharmacyclics must provide express written 
approval of, any change in the maintenance of the foregoing documen ts if the investigator wishes 
to move study records to another location or a ssign responsibility for record retention to another 
party. If the investigator cannot guarantee the archiving requirements set forth herein at his or her 
study site for all such documents, special arrang ements must be made between the investigator 
and Pharmacyclics to store such documents in sealed containers away from the study site so that 
they can be returned sealed to the investigator for audit purposes. 
12.7. Case Report Forms and Record Maintenance 
The case report forms will be used to collect th e clinical study data and must be completed for 
each enrolled subject with all required study data accurately recorded such that the information 
matches the data contained in medical records (eg, physiciansâ€™ notes, nursesâ€™ notes, clinic charts 
and other study-specific source documents). Auth orized study site personnel (ie, listed on the 
Delegation of Authority log) will complete CRFs designed for this study according to the completion guidelines that will be provided. The investigator will ensure that the CRFs are 
accurate, complete, legible, and completed within  a reasonable period of time. At all times, the 
investigator has final responsibility for the accuracy and authenticity of all clinical data. 
The CRFs exists within an electronic data capture (EDC) system with controlled access managed 
by [CONTACT_36098]. Study staff will be appropriately 
trained in the use of CRFs and application of electronic signatures before the start of the study 
and before being given access to the EDC system. Original data and any ch anges of data will be 
recorded using the EDC system, with all changes tracked by [CONTACT_135953]. The investigator attests that the information contained in the CRFs is true 
by [CONTACT_36100]. After database lock, the investigator 
will receive a copy of the subject data (eg, pape r, CD, or other appropriate media) for archiving 
at the study site. 
12.8. Investigational Study Drug Accountability 
Ibrutinib and any comparator used must be kept in a locked limited access room. The study drug 
must not be used outside the context of the protocol. Under no circumstances should the 
investigator or other site personnel supply ibrutinib or comparator to other investigators, 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217214] be noted when drug supplies are used during the 
study: 
1. Study identification number (PCYC-1140-IM) 
2. Subject identification number 
3. Lot number(s) of ibrutinib or placebo dispensed for that subject 
4. Date and quantity of drug dispensed 
5. Any unused drug returned by [CONTACT_183982], the monitor will evaluate and a pprove the siteâ€™s procedure for investigational 
product disposal/destruction to ensu re that it complies with Pharma cyclicsâ€™ requirements. If the 
site cannot meet Pharmacyclic sâ€™ requirements for disposal/d estruction, arrange ments will be 
made between the site and Ph armacyclics or its representa tive, for return of unused 
investigational product. Before disposal/destruction, final drug accountability and reconciliation 
must be performed by [CONTACT_2037]. All study supplies and associated documentation will be regularly reviewed and verified by [CONTACT_36102]. 
12.9. Study Monitoring/Audit Requirements 
Representatives of Pharmacyc lics or its designee will monito r this study until completion. 
Monitoring will be conducted through personal visits with the investigator and site staff, remote 
monitoring, as well as any appropriate communications by [CONTACT_2319], fax,  email, or telephone. 
The purpose of monitoring is to ensure that the study is conducted in compliance with the 
protocol, standard operating pr ocedures (SOPs), and other writte n instructions and regulatory 
guidelines, and to ensure the quality and integrit y of the data. This study is also subject to 
reviews or audits. 
To assure the accuracy of data collected in the CRFs, it is mandatory that the monitor/auditor 
have access to all original so urce documents, including all electronic medical records (EMR) at 
reasonable times and upon reasonable notice. If access to the EMR cannot be granted to the 
monitor, the site must ensure that all certified copi[INVESTIGATOR_183918]. During the review of source documents, 
every effort will be made to maintain the anonymity and confidentiality of all subjects during 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 75 this clinical study. However, because of th e experimental nature of this treatment, the 
investigator agrees to allow the IRB/REB/IEC, representatives of Pharmacyclics, its designated 
agents and authorized employees of the appropriate Regulatory Authority to inspect the facilities 
used in this study and, for purposes of verification, allow direct access to the hospi[INVESTIGATOR_183919]. A statement to this effect will be included in the 
informed consent and permission form authoriz ing the use of protected health information. 
Pharmacyclics or its authorized representative may perform an audit at any time during or after completion of this study. All study-related documentation must be made available to the 
designated auditor. In addition, a representative of the FDA or other Regulatory Agencies may 
choose to inspect a study site at any time before, du ring, or after completion of the clinical study. 
In the event of such an inspection, Pharmacyclics will be available to assist in the preparation. 
All pertinent study data should be  made available as requested to  the Regulatory Authority for 
verification, audit, or inspection purposes. 
12.10. Investigator Responsibilities 
A complete list of investigator  responsibilities are outlined in the clinical trial research 
agreement and the Statement of Investigator Form FDA 1572, both of which are signed by [CONTACT_183983].  In summary, the investigator will conduct the 
study according to the current protocol; will read and understand the IB; will obtain IRB/REB/IEC approval to conduct the study; will obtain informed consent from each study 
participant; will main tain and supply to the Sponsor or designee, auditors and regulatory 
agencies adequate and accurate records of  study activity and drug accountability for 
study-related monitoring, audits, IRB/REB/IEC reviews and regulatory inspections; will report 
SAEs to the Sponsor or designee and IRB/REB/ IEC according to the specifics outlined in this 
protocol; will personall y conduct or supervise the study; and will ensure that colleagues 
participating in the study are informed a bout their obligations in meeting the above 
commitments. 
12.11. Sponsor Responsibilities 
A complete list of the Sponsor responsibilities is outlined in the clin ical trial research agreement 
and in the laws and regulation of the country in which the research is c onducted. In summary, the 
Sponsor will select qualified inve stigators, provide them with the information they need to 
properly conduct the study, ensure adequate monitoring of the study, conduct the study in 
accordance with the general investigational plan and protocols and promptly inform 
investigators, health and regulatory agencies/authorities as appropriate of significant new adverse 
effects or risks with respect to the drug. 
12.12. Financial Disclosure 
A separate financial agreement will be made between each principal investigator [INVESTIGATOR_183920]. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 76 For this study, each investigator and sub-inves tigator (as designated on the Form FDA1572) will 
provide a personally signed Financial Disclosu re Form in accordance with Â§ [ADDRESS_217215] or injury, appropriate medical care as determined by [CONTACT_1275]/designee will be provided. 
The ICF will include a description of  treatment in the event of a study related injury and 
handling of the costs associated therewith, inco rporating country-specific national regulations 
and/or local laws. Financial compensation for lost wages, disability or discomfort due to the 
study is not available. 
Clinical trial insurance has been undertaken acco rding to the laws of the countries where the 
study will be conducted. An insurance certificate w ill be made available to the participating sites 
at the time of study initiation. 
12.14. Protocol Amendments 
Pharmacyclics will initiate any change to the protocol in a protocol amendment document. 
The amendment will be submitted to the IRB/REB/IEC together with, if applicable, a revised 
model ICF. Written documentation of IRB/REB/IEC and required site approval must be received 
by [CONTACT_183984]. Additionally, under this 
circumstance, information on any change in risk and/or change in scope must be provided to subjects already actively participating in the study,  and they must read, understand and sign each 
revised ICF, confirming willingness to remain in the trial. 
No other significant or consistent change in the study procedures, except to eliminate an 
immediate hazard, shall be effect ed without the mutual agreement of the investigator and 
Pharmacyclics. 
12.15. Publication of Study Results 
Pharmacyclics may use the results of this clinical study in registration documents for Regulatory 
Authorities in the US or abroad. The results may also be used for papers, abstracts, posters, or 
other material presented at scientific meetings or  published in professional j ournals or as part of 
an academic thesis by [CONTACT_2413]. In all cases, to avoid disclosures that could jeopardize 
proprietary rights and to ensure accuracy of the data, Pharmacyclics reserves the right to preview 
all manuscripts and abstracts related to this study, allowing Pharmacyclics sufficient time to 
make appropriate comments befo re submission for publication. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217216] accruals of eligible subjects shall be 
listed as lead authors on manuscripts and report s of study results. The medical monitor, study 
director and/or lead sta tistician may also be included in the list of authors. This custom can be 
adjusted upon mutual agreement of the author s and Pharmacyclics and in accordance with 
current standards for authorship as recorded in  professional conference  and journal submission 
instructions. 
12.16. Study Discontinuation 
The Sponsor reserves the right to terminate the study at any time. Should this be necessary, both 
the Sponsor and the investigator will arrange discontinuation procedures . In terminating the 
study, the Sponsor and the investigator will assure  that adequate consideration is given to the 
protection of the subjectsâ€™ interests.   
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 78 13. REFERENCES 
Allen JL, Tata PV, Fore MS et al. Increased BCR responsiveness in B cells from patients with chronic 
GVHD. Blood. 2014;123:2108-15. 
Anasetti C, Logan BR, Lee SJ, et al. Increased incidence of chronic graft-versus-host disease (GVHD) 
and no survival advantage with filgrastim-mobilized peripheral blood stem cells (PBSC) compared to 
bone marrow (BM) transplants from unrelated donors: results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phas e III, prospective, randomized trial. ASH Annual 
Meeting Abstracts 2011;118: Abstract 1. 
Appelbaum FR, Haematopoietic cell transplantati on as immunotherapy. Nature 2001; 411:385-9. 
Arai S, Jagasia M, Storer B, et al. Global and organ-specific chronic graft-versus-host disease severity 
according to the 2005 NIH Consensus Criteria. Blood. 2011;118:4242-49.  
Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and 
prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. 
Biol Blood Marrow Transplant. 2001;7:265-73. 
Baird K, Pavletic SZ. Chronic graft versus host  disease. Curr Opin Hematol. 2006;13:426-435.  
Brunton LL, Chabner BA, Knollmann BC (Eds). The Pharmacological Basis of Therapeutics, 12th ed. 
McGraw Hill, [LOCATION_001] 2011. p.1216. Carpenter PA, Kitko CL, Elad S, et al. National Institutes of Health Consensus Development Project on 
Criteria for Clinical Trials in Chronic Graft-ve rsus-Host Disease: V. The 2014 Ancillary Therapy and 
Supportive Care Working Group Report. Biol  Blood Marrow Transplant. 2015;21:1167-87. 
Child CG, Turcotte JG. â€œSurgery and portal hypertensionâ€. In Child CG. The liver and portal 
hypertension. Philadelphia:Saunders. 1964. pp. 50-64.  
Dignan FL, Amrolia P, Clark A, et al. Diagnosis and management of chronic graft-versus-host disease. Br 
J Haematol. 2012;158:46-61. 
Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibruti nib is an irreversible molecular inhibitor of ITK 
driving a Th1-selective pressure in T lymphocytes. Blood 2013;122:2539â€“49. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project 
on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group 
report. Biol Blood Marrow Transplant 2005;11:945-956. 
Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125:606-15. 
Review. 
Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-
host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214-9. 
Flynn R, Du J, Veenstra RG, et al. Increased T follicular helper cells and germinal center B cells are 
required for cGVHD and bronchiolit is obliterans. Blood. 2014;123:3988-98. 
Gilman AL, Schultz KR, Goldman FD, et al. Randomized trial of hydroxychloroquine for newly 
diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study. Biol Blood Marrow Transplant. 2012;18:84-91.  
Hale GA, Shrestha S, Le-Rademacher J, et al. Alternate donor hematopoietic cell transplantation (HCT) 
in non-Hodgkin lymphoma using lower intensity conditioning: A Report from the CIBMTR. Biol Blood Marrow Transplant 2012;18:1036-1043. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 79 Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic 
target for treatment of chronic lymphocytic leukemia and is effectively targeted by [CONTACT_9090]-[ZIP_CODE]. 
Blood. 2011;117:6287-96. 
Holler E. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. 
Best Pract Res Clin Haematol. 2007;20:281-294.  
International Conference on Harmonization (ICH) Gu ideline for Industry: Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting (ICH-E2A). March 1995. 
International Conference on Harmonisation (ICH) of Technical Requirements for Registration of 
Pharmaceuticals for Human Use: ICH Harmonised Tripartite Guideline: Guidance for Good Clinical 
Practice (ICH-E6)(R1). June 1996.   
Inamoto Y, Savani BN, Shaw BE, et  al. Secondary solid cancer screening following hematopoietic cell 
transplantation. Bone Marrow Transplant. 2015.[Epub ahead of print]. 
Investigator's Brochure. Ibrutinib. Version 12.0:  11 December 2018. Pharmacyclics LLC; Janssen 
Research & Development, LLC. 
Jacobsohn DA, Kurland BF, Pi[INVESTIGATOR_43221] J, et al. Co rrelation between NIH composite skin score, 
patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. 
Blood. 2012;120:2545-52. 
Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on 
Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging 
Working Group report. Biol Blood Marrow Transplant. 2015;21:389-401. 
Johnston HF, Xu Y, Racine JJ, et al. Administration of anti-CD20 mAb is highly effective in preventing 
but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects. Biol Blood Marrow Transplant. 2014;20:1089-103. 
Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-
host disease. Blood. 2000;96:3995-6. 
Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized 
trial comparing cyclosporine plus prednisone versus prednisone alon e. Blood 2002;100:48-51. 
Lee SJ, Wolff D, Kitko C, et al. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. 
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic 
Graft-versus-Host Disease: IV. The 2014 Response CriteriaWorking Group Report. Biol Blood Marrow 
Transplant. 2015;21:984-999. 
Lee JW, Deeg HJ. Prevention of chronic GVHD. Best Pract Res Clin Haematol. 2008;21:259-270.  
Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 
2003;9:215-233.  
Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term 
survivors after hematopoietic cell transplantat ion. Biol Blood Marrow Transplant. 2012;18:348â€“71. 
Martin PJ, Inamoto Y, Carpenter PA, Lee SJ, Flow ers ME. Treatment of chronic graft-versus-host 
disease: Past, present and future. Korean J Hematol. 2011;46(3):153-63.  
Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of 
chronic graft-versus-host disease. Blood 2009;113:5074-82. 
Miklos DB, Kim H, Zorn E, et al. Antibody Res ponse to DBY [CONTACT_183985]. Blood 2004;103:353-359. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217217] dise ase and disease remission. Blood 2005;105:2973-2978. 
NCI Common Terminology Criteria for Adverse Events. Version 4.03. 2010. 
Olivieri A, Cimminiello M, Corradini P, et al. Long-term outcome and prospective validation of NIH 
response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood. 2013;122:4111-8.  
Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. 
ChemMedChem 2007;2:58-61. 
Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: CIBMTR 
Summary Slides, 2015 (http://www.cibmtr.org). 
Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host-disease: 
national institutes of health consensus development project on criteria for clinical trials in chronic graft-
versus-host-disease: IV. Response criteria workin g group report. Biol. Blood Marrow Transplant. 
2006;12:252-66. 
Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without 
alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. 
Blood. 2002;100:3121-3127. 
Pi[INVESTIGATOR_43221] J, Kurland B, Chai X, et al. Patient-reported qu ality of life is associated with severity of chronic 
graft-versus-host disease as measured by [CONTACT_183986]: report on baseline data from the Chronic GVHD 
Consortium. Blood. 2011;117:4651-4657.  Pugh RN, Murray-Lyon IM, Dawson L, et al. â€œTrans ection of the oesophagus for bleeding oesophageal 
varicesâ€. The British Journal of Surgery, 1973;60: 646-9. 
RAYOS (prednisone) delayed-release tablets. Prescribing Information. Horizon Pharma [LOCATION_003] Inc. 
Deerfield, IL; 2013. 
Sahaf B, Arai S, Otani J, et al. Rituximab Prov ides Steroid-Sparing Therapy in New-Onset Chronic 
Graft-Versus-Host Disease. AS BMT 2013;19,S140. Abstract 55. 
Sarantopoulos S, Blazar BR, Cutler C, et al. B cells in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:16-23.  
Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human 
chronic graft-versus-host disease. Blood. 2009;113:3865-3874.  Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the 
pathogenesis of graft-versus- host disease. Blood. 2009;114:4919-4927. 
Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic diagnosis of chronic graft-versus-host disease: 
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic 
Graft-versus-Host Disease: II. Pathology Work ing Group Report. Biol Blood Marrow Transplant 
2006;12:31-47. 
Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among 
patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 
2013;309:1359â€“67. 
Sullivan KM, Witherspoon RP, Storb R,  et al. Prednisone and azathioprin e compared with prednisone and 
placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged 
thrombocytopenia after allogeneic marrow transplantation. Blood 1988;72:546-54. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 81 Syrjala KL, Martin PJ, Lee SJ. Delivering care to long-term adult survivors of hematopoietic cell 
transplantation. J Clin Oncol. 2012;30:3746-51. 
Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients 
receiving radiation and chemothera py. N Engl J Med. 1957; 257:491-6. 
USPI [INVESTIGATOR_183921]Â® (ibrutinib) revised August 2017, Pharmacyclics LLC. 
Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic 
GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow 
Transplant.2011;17:1-17. 
  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
  FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 82 14. APPENDICES 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 86 Footnote: 
a The physical examination will include, height (at Screening for adults, and at Screening and annually for subjects <22 years of  age at the time of enrollment), 
weight, and examination per clinical practice.  
b Confirm eligibility and randomize within [ADDRESS_217218] dose. 
c ECGâ€™s may be performed at the investigatorâ€™s discretion, particularly in subjects with arrhythmic symptoms (eg, palpi[INVESTIGATOR_814], l ightheadedness) or new onset of 
dyspnea. At Week 2 12-lead ECG (subject in supi[INVESTIGATOR_36068] 10 min prior to ibrutinib dose) performed o n subjects <[ADDRESS_217219] udy nurse or physician.  
f Pharmacokinetic (PK) samples will be drawn for all subjects according to the schedule in Appendix B  predose specimen is required. Pharmacodynamic (PD), 
T/B/NK and Biomarker sampling will be performed on selected days. Refer to  Appendix B for more details. 
g Hematology and Serum Chemistry may be done within 3 days of Day 1. 
h The cGVHD Response assessment, Lee cGVHD Symptom Scale, SF-36, and FEV1 may be done from 7 days prior to Week 25/49 to 21 days after Week 25/49. 
If FEV1 results are abnormal at Screening FEV1 should be obtained every [ADDRESS_217220] enrollment only for subjects <22yrs of age at enrollment . Adolescents (<22 years of age at 
the time of enrollment) will be followed for up to 5 years after enrollment and may be rolled-over to a long-term extension stu dy during late-effects follow-up. 
k cGVHD should be evaluated prior to start of prednisone (if initiated during Screening) or prior to Week1 Day 1 start of prednis one and ibrutinib/placebo. 
l cGVHD response assessments and PRO measures at EOT visit need not be repeated if performed within the previous [ADDRESS_217221]. 
 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 87 Appendix B. Schedule of Assessments for Pharmacokinetics, Pharmacodynamics, 
Biomarker and T/B/NK 
Day 1,  
Week Time Pharmacokinetics Pharmacodynamics Biomarkers T/B/NK 
Screening    
X Â¼Ä® X 
1 Predose  X X Â¼Ä®Èƒ   X 
2 Predosea 
(trou gh value) X   
 
1h post doseb (Â± 
15 min) X   
 
[ADDRESS_217222] doseb (Â± 
15 min) X   
 
[ADDRESS_217223] doseb (Â± 
30 min) X   
 
[ADDRESS_217224] doseb (Â± 
1 h)  X   
 
5 Predose  X X Â¼Ä® X 
9 Predose  X X Â¼Ä®Èƒ X 
13 Predose  X X Â¼Ä® X 
17 Predose  X X Â¼Ä®Èƒ X 
21 Predose  X X Â¼Ä® X 
25 Predosea (trough 
value) X X X Â¼Ä®Èƒ X 
1h post doseb (Â± 
15 min) X   
 
[ADDRESS_217225] doseb (Â± 
15 min) X  
[ADDRESS_217226] doseb (Â± 
30 min) X   
 
[ADDRESS_217227] doseb (Â± 
1 h)  X   
 
37 Predose   
X â‚¬ X 
49 Predose  X X Â¼Ä®Èƒ X 
73 Predose  X X â‚¬ X 
97 Predose  X X Â¼Ä® X 
Progressive 
Disease Visit   X X Â¼Ä® X 
Sample Collection Tube Type  NaHep 
(2mL) ACD  
(8.5 mL) â‚¬=EDTA 
(10 mL), 
Ä®=ACD 
(8.5 mL) 
N=NaHep 
(10 mL) EDTA 
(10 ml) 
a Sample collected 24 hours (Â± 2 hours) after last intake and prior to dosing on that PK day (applies only on days when PK is col lected). 
b Record actual time of sample collection (applies only on days when PK is collected). 
The same timepoints as Week 2 and Week 25 PK sample collection will be followed. If ibrutinib/placebo is on hold during schedul ed Week 2 
and 25 Week PK evaluation, PK testin g should be obtained on the next scheduled visit after ibrutinib dose has been stable for 7 da ys.  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3  06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 88 Appendix C. Karnofsky/Lansky Performance Status  
.DUQRIVN\6FDOHUHFLSLHQWDJHÂ•\HDUV  Lansky Scale (recipi[INVESTIGATOR_29039] <16 years)  
Able to carry on normal activity; no special care 
is needed  Able to carry on normal activity; no special care is needed  
[ADDRESS_217228] needs 60  Ambulatory up to 50% of time, limited active play with assistance/supervision 
50  Requires considerable assistance and frequent medical care 50  Considerable assistance required for any active play, fully able to engage in quiet play 
Unable to care for self, requires equivalent of institutional or hospi[INVESTIGATOR_10422], disease may be progressing rapi[INVESTIGATOR_183922] 
40  Disabled, requires special care and 
assistance 40  Able to initiate quiet activities 
30  Severely disabled, hospi[INVESTIGATOR_373], although death not imminent 30  Needs considerable assistance for quiet activity 
20  Very sick, hospi[INVESTIGATOR_20545] 20  Limited to very passive activity initiated by [CONTACT_2312] (eg, TV) 
10  Moribund, fatal process progressing 
rapi[INVESTIGATOR_375] 10  Completely disabled, not even passive play 
 
  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3  06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 89 Appendix D. Inhibitors and Inducers of CYP3A 
Inhibitors and inducers of CYP3A enzymes are defined as follows. Refer to Section 6.2.1  on instructions 
for concomitant use of CYP3A inhibitors and inducers with ibrutinib. Further information can be found at 
the following website: http://medicine.iupui.edu/clinpharm/ddis/main-table/. 
Inhibitors of CYP3A Inducers of CYP3A 
Strong inhibitors:  carbamaze 
indinavir nevira pi[INVESTIGATOR_183923] g CYP3A inducers  
telithrom ycin avasimibe 
cobicistat carbamaze pi[INVESTIGATOR_183924]. Johnâ€™s Wort 
voriconazole  
Moderate inhibitors:   
aprepi[INVESTIGATOR_183925]:   
cimetidine  
fluvoxamine  
All other inhibitors:   
chloram phenicol  
delavirdine   
gestodene  
mifepristone  
norfloxacin  
star fruit  
a  Itraconazole and ketoconazole will be replaced with voriconazole for study subjects 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 90 Appendix E. Child-Pugh Score for Subjects with Chronic Liver Impairment 
Measure 1 point 2 points 3 points 
7RWDOELOLUXELQÈPRO/PJG/  <34 (<2) 34-50 (2-3) >50 (>3) 
Serum albumin, g/L (g/dL) >35 (>3.5) 28-35 (2.8-3.5) <28 (<2.8) 
PT/INR <1.7 1.71-2.30 >2.30 
Ascites None Mild Moderate to Severe 
Hepatic encephalopathy None Grade I-II (or suppressed 
with medication) Grade III-IV  (or refractory) 
 
Points Class 
5-6 A 
7-9 B 
10-15 C 
  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 93 Appendix G. SF-36 Questionnaire 

IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 94  
 

IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 95  
 

IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 96  

IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 97  
 

IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 98  
 

IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 101  SCORE 0 SCORE 1 SCORE 2 SCORE 3 
LUNGS  No symptoms  Mild 
symptoms 
(shortness of breath after climbing one 
flight of steps) 
 Moderate 
symptoms 
(shortness of breath after walking on flat 
ground) 
 Severe symptoms 
(shortness of breath 
at rest; requiring 0
2) 
 Abnormality present but explained entirely by [CONTACT_105]-GVHD documented cause 
(specify):_______________________ 
JOINTS AND 
FASCIA  No symptoms   Mild tightness 
of arms or 
legs, normal or mild decreased 
range of 
motion (ROM) 
AND not affecting ADL  
 Tightness of arms 
or legs OR joint contractures, erythema thought 
due to fasciitis, 
moderate decrease 
ROM AND mild to moderate 
limitation of ADL  
 Contractures WITH 
significant decrease 
of ROM AND significant 
limitation of ADL 
(unable to tie 
shoes, button shirts, dress self, etc.)  
 Abnormality present but explained entirely by [CONTACT_105]-GVHD documented cause 
(specify):_______________________  
Reference:  
 
Lee SJ, Wolff D, Kitko C, et al. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response CriteriaWorking Group Report. Biol Blood Marrow Transplant. 2015;21:984-999.  

IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 102 Appendix I. Response Determination for Chronic GVHD  Clinical Trials based on Clinician Assessments 
 

IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 103 Overall Response: 
Skin, mouth, liver, upper and lower GI, esophagus, lung, eye, and joint/fascia are the organs or sites considered in evaluating  overall 
response.  
x Complete Response (CR) is define d as resolution of all manifesta tions in each organ or site  
x Partial Response (PR) is defined as improvement in at least 1 organ or s ite without progression in any other organ or site. 
x Disease Progression is defined as clinically meaningful worsening in one or more or gans regardless of imp rovement in other 
organs. Mixed Response: CR or PR in at least 1 organ accompan ied by [CONTACT_183987]. 
x Stable disease (SD): response that  does not meet the criteria for CR , PR, or disease progression. 
      If a patient shows overall cGVHD improvement while organ responses indicate progression in one or more organs, cGVHD 
assessment should be repeated at a diffe rent time point, to confirm progression, before discontinuing study drug. Response 
assessments coinciding with chr onic GVHD flares (transient worsening of organs that were previously involved) will be inevaluab le 
and should be repeated as soon as the flar e resolves or at the next assessment time point. If progression is confirmed, time to 
progression will be calculated using first da te of disease progression. Lack of Respons e includes categories of disease progres sion or 
stable disease.  
Lee SJ, Wolff D, Kitko C, et al. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of He alth Consensus Development 
Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Repo rt. Biol Blood Marrow 
Transplant. 2015;21:984-999.  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 104 Appendix J. Chronic GVHD Activity Assessment  Patient Self Report 
 
Todayâ€™s Date: ________________________   MR#/Name: ________________________ 
 
CHRONIC GVHD ACTIVITY ASSESSMENT-PATIENT SELF REPORT 
 
Reference:  
Lee SJ, Wolff D, Kitko C, et al. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National 
Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host 
Disease: IV. The 2014 Response Criteria Working Group Report. Biol Blood Marrow Transplant. 2015;21:984-999. Symptoms 
  
 
Not                                                                                                                 As Bad As 
You 
Present                                                                                                            Can Imagine 
 
 
  [ADDRESS_217229] below from 0 (symptom 
has not been present) to 10 (the 
symptom was as bad as you can 
imagine it could be) for each item. 
Your skin itching  at its WORST? O O  O O O O O O O O O 
Your skin and/or joint tightening  at 
their WORST? O O O O O O O O O O O 
Your mouth sensitivity at its 
WORST? O O  O O O O O O O O O 
Your genital discomfort  at its 
WORST? (Women â€“ vagina, vulva, or labia) 
(Men â€“ penis ) O O O O O O O O O O O 
Eyes What is your main complaint with regard to your eyes? 
 
 
Please rate how severe this symptom is, from 0 (not 
at all severe) to 10 (most severe): 0    1     2    3    4    5     6    7    8    9    
10 
 
Patient Global Ratings: 
 
1. Overall, do you think that your chronic graft versus host disease is mild, moderate or severe? 
1= mild 2=moderate 3=severe 
 
2. Please circle the number indicating how severe your chronic graft versus host disease symptoms are, where [ADDRESS_217230] severe cGvHD                                           
not at all severe                                                                                                             s ymptoms  possible 
 3. Compared to a month ago, overall would you say that your cGvHD symptoms are: 
 
+3= Very much better 
+2= Moderately better +1=A little better 
 0= About the same 
-1=A little worse -2=Moderately worse 
-3=Ver
y much worse  FORM B 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 105 Appendix K. Prednisone Equivalents Table 
Corticosteroid Doses Equiva lent to 20 mg Prednisone 
Corticosteroid Equivalent dose  
(mg) 
Prednisone  20 
Cortisone 100 
Cortisol 80 
Hydrocortisone 80 
Prednisolone 20 
Methylprednisolone 16 
Triamcinolone 16 
Betamethasone 3 
Dexamethasone 3 
Source: 
Brunton LL, Chabner BA, Knollmann BC (Eds). The Pharmacological Basis of Therapeutics, 12th ed. McGraw 
Hill, [LOCATION_001] 2011. p.1216.   
 
  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 106 Appendix L. Summary of Ancillary Therapy and Supportive Care Interventions 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 107 Organ System Organ-Specific Intervention* 
 Prevention Treatment 
Skin and appendages Photoprotection -sun avoidance and 
physical sunblocks (eg, protective 
clothing, UVA, and UVB 
sunscreens). Avoidance of 
photosensitizing agents (eg, voriconazole). Surveillance for 
malignancy [ Inamoto 2015 , 
Majhail 2012 ]. For intact skin topi[INVESTIGATOR_183926], 
corticosteroids, antipruritic agents, 
and others (eg, PUVA or narrow band 
UVB, calcineurin inhibitors).  
For erosions/ulcerations e 
microbiologic cultures, topi[INVESTIGATOR_183927], protective films or 
other dressings, debridement, hyperbaric oxygen, wound care 
specialist consultation. 
Mouth and oral cavity Maintain good oral/dental hygiene. 
Routine dental cleaning and 
radiographs. Surveillance for 
infection and malignancy. 
Nutritional counseling, if needed. Topi[INVESTIGATOR_183928]-high potency 
corticosteroids and topi[INVESTIGATOR_110404]. Topi[INVESTIGATOR_39671]. 
Therapy for oral dryness (eg, salivary 
stimulants, sialogogues) and for prevention of related complications 
(ie, dental decay). 
Eyes Photoprotection. Surveillance for 
infection, cataract formation, and 
increased intraocular pressure. Artificial tears, ocular ointments, 
topi[INVESTIGATOR_183929], punctal occlusion, 
humidified environment, occlusive 
eye wear, moisture chamber eyeglasses, cevimeline, pi[INVESTIGATOR_1227], 
gas-permeable scleral contact [CONTACT_13293], 
autologous serum, microbiologic 
cultures, topi[INVESTIGATOR_166464], 
doxycycline. 
Vulva and vagina Surveillance for estrogen deficiency, 
infection (HSV, HPV, yeast, 
bacteria) and malignancy 
[Majhail 2012 ]. Water-based or silicone lubricants, 
topi[INVESTIGATOR_4575], topi[INVESTIGATOR_155018], dilators or vibrators, 
surgery for extensive synechiae or 
obliteration, early gynecology 
consultation. Avoid glycerin, paraben, 
fragrance, and other additive products. 
Gastrointestinal tract and liver Surveillance for infection (viral, bacterial, fungal, parasites) Rule out other potential etiologies. Dietary modification, enzyme 
supplementation for pancreatic 
insufficiency, bile salt resins, 
gastroesophageal reflux management, 
esophageal dilatation, 
ursodeoxycholic acid, topi[INVESTIGATOR_183930], limitation of ethanol 
intake, avoidance of hepatotoxins. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 108 Organ System Organ-Specific Intervention* 
 Prevention Treatment 
Lungs Surveillance for infection 
(Pneumocystis jiroveci, viral, 
fungal, bacterial). Rule out other potential etiologies (eg, 
infection, gastroesophageal reflux). 
Inhaled corticosteroids, 
bronchodilators, supplementary 
oxygen, pulmonary rehabilitation. Consideration of lung transplantation 
in appropriate candidates. 
Hematopoietic Surveillance for infection (CMV, 
parvovirus) Rule out other potential etiologies (eg, 
drug toxicity, infection). 
Hematopoietic growth factors, 
immunoglobulin for immune 
cytopenias 
Neurologic Calcineurin drug level monitoring. 
Seizure prophylaxis as indicated, 
including blood pressure control, 
electrolyte replacement, 
anticonvulsants. EMG monitoring 
and staging in symptomatic patients 
taking medications known to cause neuropathy. Close monitoring of 
distal extremities for wounds in 
insensate patients. Occupational and physical therapy to 
prevent falls and improve function, treatment of neuropathic syndromes 
with tricyclic antidepressants, SSRI, 
or anticonvulsants [ Smith 2013]. 
Orthotics and assistive devices (canes and walkers). Bracing, splinting or surgical release for entrapment 
neuropathies. 
Immunologic and 
infectious diseases Immunizations and prophylaxis against Pneumocystis jirovecii, 
VZV, and encapsulated bacteria 
based on CDC guidelines. Consider immunoglobulin replacement based 
on levels and recurrent infections. 
Surveillance for infection (viral, 
bacterial, fungal, atypi[INVESTIGATOR_2855]). Organism-specific antimicrobial agents. Empi[INVESTIGATOR_183931]-
spectrum antibacterial coverage for 
fever. 
Musculoskeletal Surveillance for decreased ROM, 
bone densitometry, calcium levels 
and 25-OH vitamin D. Physical therapy, calcium, vitamin D, and 
bisphosphonates. Flexion-extension 
x-rays to look for instability. Physical therapy, bisphosphonates for osteopenia, and osteoporosis. Spi[INVESTIGATOR_183932]/or intractable pain. Walking program, 
resistance training, core strengthening. 
SSRI indicates selective serotonin reuptake inhibitors; CDC, Centers for Disease Control.  
*In general, close serial monitoring of all organ systems is recommended to promote early detection and intervention directed toward reversing or preventing progression of chronic GVHD manifestations 
and treatment-associated toxicities. Ancillary and supportive care therapi[INVESTIGATOR_183933], although in some cases their use may circumvent the need for 
systemic treatment or allow doses of systemic agents to be reduced. 
 
Carpenter PA, Kitko CL, Elad S. National Institutes of Health Consensus Development Project on 
Criteria for Clinical Trials in Chronic Graft-ve rsus-Host Disease: V. The 2014 Ancillary Therapy and 
Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2015;21:1167â€“87.  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 109 Inamoto Y, Savani BN, Shaw BE, et  al. Secondary solid cancer screening following hematopoietic cell 
transplantation. Bone Marrow Transplant. 2015.[Epub ahead of print]. 
Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term 
survivors after hematopoietic cell transplantat ion. Biol Blood Marrow Transplant. 2012;18:348â€“71.  
Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among 
patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 
2013;309:1359â€“67.  
 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 110 Appendix M. Diagnosis of cGVHD  Signs and Symptoms of cGVHD 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 111 ORGAN OR SITE DIAGNOSTIC 
(Sufficient to establish the 
diagnosis of chronic GVHD) DISTINCTIVEa  
(Seen in chronic GVHD, but insufficient alone to establish a diagnosis) OTHER FEATURES OR 
UNCLASSIFIED ENTITIES
b  COMMONc  
(Seen with both acute and 
chronic GVHD) 
Skin x Poikiloderma  
x Lichen planus-like features  
x Sclerotic features  
x Morphea-like features 
x Lichen sclerosus-like 
features x Depi[INVESTIGATOR_371] 
x Papulosquamous lesions x Sweat impairment 
x Ichthyosis 
x Keratosis pi[INVESTIGATOR_22785] 
x Hypopi[INVESTIGATOR_371] 
x Hyperpi[INVESTIGATOR_371] x Erythema 
x Maculopapular rash 
x Pruritus 
Nails  x Dystrophy 
x Longitudinal ridging, splitting or brittle features 
x Onycholysis 
x Pterygium unguis 
x Nail loss (usually 
symmetric, affects most 
nails)   
Scalp and body hair  x New onset of scarring or 
nonscarring scalp alopecia 
(after recovery from chemoradiotherapy) 
x Loss of body hair 
x Scaling x Thinning scalp hair, 
typi[INVESTIGATOR_91608], coarse 
or dull (not explained by [CONTACT_183988]) 
x Premature gray hair  
Mouth  x Lichen planus-like changes x Xerostomia 
x Mucoceles 
x Mucosal atrophy 
x Ulcers 
x Pseudomembranes  x Gingivitis 
x Mucositis 
x Erythema 
x Pain 
Eyes  x New onset dry, gritty, or 
painful eyes 
x Cicatricial conjunctivitis 
x Keratoconjunctivitis sicca  
x Confluent areas of punctate 
keratopathy x Photophobia 
x Periorbital 
hyperpi[INVESTIGATOR_371] 
x Blepharitis (erythema of the eyelids with edema)  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 112 ORGAN OR SITE DIAGNOSTIC 
(Sufficient to establish the 
diagnosis of chronic GVHD) DISTINCTIVEa  
(Seen in chronic GVHD, but insufficient alone to establish a diagnosis) OTHER FEATURES OR 
UNCLASSIFIED ENTITIES
b  COMMONc  
(Seen with both acute and 
chronic GVHD) 
Genitalia x Lichen planus-like features 
x Lichen sclerosus-like 
features x Erosions 
x Fissures   
Females x Vaginal scarring or 
clitoral/labial agglutination x Ulcers   
Males x Phimosis or urethral/meatus scarring or stenosis    
GI Tract x Esophageal web 
x Strictures or stenosis in the 
upper to mid third of the esophagus  x Exocrine pancreatic 
insufficiency x Anorexia 
x Nausea 
x Vomiting 
x Diarrhea 
x Weight loss 
x Failure to thrive 
(infants 
x and children 
Liver    x Total bilirubin, 
alkaline phosphatase 
>2 x upper limit of 
normal 
x ALT >2 x upper limit 
of normal 
Lung x Bronchiolitis obliterans 
diagnosed with lung biopsy  
x Bronchiolitis obliterans 
syndrome (BOS)d x Air trappi[INVESTIGATOR_183934] x Cryptogenic organizing pneumonia (COP)
e 
x Restrictive lung diseasee  
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 113 ORGAN OR SITE DIAGNOSTIC 
(Sufficient to establish the 
diagnosis of chronic GVHD) DISTINCTIVEa  
(Seen in chronic GVHD, but insufficient alone to establish a diagnosis) OTHER FEATURES OR 
UNCLASSIFIED ENTITIES
b  COMMONc  
(Seen with both acute and 
chronic GVHD) 
Muscles, fascia, 
joints x Fasciitis 
x Joint stiffness or 
contractures secondary to 
fasciitis or sclerosis x Myositis or polymyositisf x Edema 
x Muscle cramps 
x Arthralgia or arthritis  
Hematopoietic and 
Immune   x Thrombocytopenia 
x Eosinophilia 
x Lymphopenia 
x Hypo- or hyper-
gammaglobulinemia 
x Autoantibodies (AIHA, 
ITP) 
x Raynaudâ€™s phenomenon  
Other   x Pericardial or pleural 
effusions 
x Ascites 
x Peripheral neuropathy 
x Nephrotic syndrome 
x Myasthenia gravis 
x Cardiac conduction 
abnormality or 
cardiomyopathy  
Abbreviations: ALT indicates alanine aminotransferase; AIHA, autoimmune hemolytic anemia; ITP, idiopathic thrombocytopenic purpura. 
a In all cases, infection, drug effect, malignancy, or other causes must be excluded. 
b Can be acknowledged as part of the chronic GVHD manifestations if diagnosis is confirmed. 
c Common refers to shared features by [CONTACT_91647]. 
d BOS can be diagnostic for lung chronic GVHD only if distinctive sign or symptom present in another organ (see text). 
e Pulmonary entities under investigation or unclassified. 
f Diagnosis of chronic GVHD requires biopsy. 
 
Jagasia HM, Greinix HT, Arora M, et al. Biol Blood Marrow Transplant.2015;21:389â€“401 .
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 114 Appendix N. Staging of cGVHD  
 

IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 115 

IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 116  
Source: 
Jagasia HM, Greinix HT, Arora M, et al. Biol Blood Marrow Transplant.2015;21:389â€“401.  

IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 117 Appendix O. NIH Global Severity/Staging of cGVHD 
Mild chronic GVHD 
[ADDRESS_217231] 1 organ (not lung) with a score of [ADDRESS_217232] 1 organ with a score of 3 
OR 
Lung score of 2 or 3 
 
Key points: 
x In skin: higher of the 2 scores to be used for calculating global severity. 
x In lung: FEV1 is used instead of clinical score for calculating global severity. 
x If the entire abnormality in an organ is noted to be unequivocally explained by a non-GVHD 
documented cause, that organ is not included for calculation of the global severity. 
x If the abnormality in an organ is attributed to multifactorial causes (GV HD plus other causes) the 
scored organ will be used for calculation of the global severity regardless of the contributing causes 
(no downgrading of organ severity score). 
Reference: 
Jagasia HM, Greinix HT, Arora M, et al. Biol Blood Marrow Transplant.2015;21:389â€“401. 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 118 Appendix P. Late Effects Surveillance for Adolescents 
In addition to procedures listed in Appendix A  and Appendix B , aGROHVFHQWVÂ•WR 22 years of 
age at the time of randomization) will be monitored for growth and development, immune 
reconstitution, and late effects up to [ADDRESS_217233] randomization. 
 Screening Week 49 Â±7 days At month 24, 36, 
48, 60 Â±30 days  
Additional measurements    
Height and Weight X X X 
Tanner Stage X X X 
Immune Reconstitutiona Tests  X X 
History of Late Effects (chart review) X X Xb 
a Immune reconstitution studies will include the following studies obtained as part of standard of 
care: 
o T and B cell enumeration 
o Quantitative Immunoglobulins 
o Post-vaccination titers 
b Are obtained annually. Post vaccination studies may not be performed annually 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment [ADDRESS_217234] Review for Transplant-Related Late Effects 
 
Symptom   
No yes 
Date of 
Diagnosis Was therapy 
Given? Was therapy still 
given at the time 
this assessment 
Diabetes/hyperglycemia requiring 
chronic treatment     
Hyperlipi[INVESTIGATOR_183935] (testosterone or 
estrogen/progesterone)      
Growth hormone deficiency/short stature     
Avascular necrosis     
Osteoporosis     
Osteoporotic fracture     
Depression or anxiety requiring therapy     
Post-traumatic stress disorder requiring therapy     
Cataracts     
Other impairment or disease     
B-cell immune deficiency     
vaccines received over the last year   If vaccines administered complete immunization CRF 
Tanner Stage  
Boys â€“ Development of external genitalia 
Stage 1:  Prepubertal 
Stage 2:  Enlargement of scrotum and testes; scrotum skin reddens and changes in texture 
Stage 3:  Enlargement of penis (length at first); further growth of testes 
Stage 4:  Increased size of penis with growth in breadth and development of glans; testes and 
scrotum larger, scrotum skin darker 
Stage 5:  Adult genitalia 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 120 Girls â€“ Breast development 
Stage 1:  Prepubertal 
Stage 2:  Breast bud stage with elevation of breas t and papi[INVESTIGATOR_9387]; enlargement of areola 
Stage 3:  Further enlargement of breast and ar eola; no separation of their contour 
Stage 4:  Areola and papi[INVESTIGATOR_141878] a second ary mound above level of breast 
Stage 5:  Mature stage: projection of papi[INVESTIGATOR_141877], related to recession of areola 
Boys and Girls â€“ Pubic hair Stage 1:  Prepubertal (can see velus ha ir similar to abdominal wall) 
Stage 2:  Sparse growth of long, slightly pi[INVESTIGATOR_183936], straight or curled, at base of penis or 
along labia 
Stage 3:  Darker, coarser and more curled hair, spreading sparsely over junction of pubes 
Stage 4:  Hair adult in type, but covering smaller area than in adult; no spread to medial surface 
of thighs 
Stage 5:  Adult in type and quantity, with  horizontal distribution (â€œfeminineâ€) 
IMBRUVICAÂ® (ibrutinib) PCYC-1140-IM Amendment 3 06 February 2019 
FINAL 
Pharmacyclics LLC Proprietary and Confidential Page 121 Appendix Q. Corticosteroid-related toxicities and CTCAE preferred terms 
Corticosteroid symptom CTCAE graded AE 
Glucose intolerance related to steroid use Glucose intolerance 
Elevated lipi[INVESTIGATOR_183937], Cholesterol high 
Hypertension Hypertension 
Steroid myopathy  Generalized muscle weakness 
Steroid skin toxicity (eg, striae, thinning of skin, 
etc.) Skin atrophy 
Neuropsychiatric symptoms including insomnia Insomnia, Agitation, Psychosis, or other psychiatric 
symptoms 
Oral/vaginal candidiasis or uncomplicated zoster infection Mucosal infection (e.g. oral/vaginal candidiasis) 
Any other infection Infections  
Diabetic nephropathy-related to steroid use Proteinuria 
Posterior reversible encephalopathy Encephalopathy, Reversible posterior 
leukoencephalopathy syndrome 
Abnormal bone density (>than - 2 Z score) Osteopo rosis (Osteopenia with a t-score -1 to -2.5) 
Insufficiency (pathologic) bone fractures Fracture 
Adrenal insufficiency  Adrenal insufficiency 
Gastrointestinal perforation Gastric perforation, Esophageal perforation, 
Duodenal perforation, Colonic perforation, Ileal 
perforation 
Peptic ulcer disease Duodenal ulcer 
Osteonecrosis of bones (avascular necrosis) Periodontal disease, Avascular necrosis 
Tendon rupture Musculosceletal and connective disorders, other 
Retinopathy (diabetic or central serous (choroidal) retinopathy) Retinopathy 
Intraocular pressure elevation Glaucoma, papi[INVESTIGATOR_183938], other 
Posterior subcapsular cataract Cataract 
 